0001144204-18-059603.txt : 20181114 0001144204-18-059603.hdr.sgml : 20181114 20181114100218 ACCESSION NUMBER: 0001144204-18-059603 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181114 DATE AS OF CHANGE: 20181114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CASI Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0000895051 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 581959440 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-20713 FILM NUMBER: 181180988 BUSINESS ADDRESS: STREET 1: 9620 MEDICAL CENTER DR STREET 2: STE 300 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-864-2600 MAIL ADDRESS: STREET 1: 9620 MEDICAL CENTER DR STREET 2: STE 300 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ENTREMED INC DATE OF NAME CHANGE: 19960415 10-Q 1 tv506426_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to _____________.

Commission file number 0-20713

CASI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		58-1959440
(State or other jurisdiction of		(I.R.S. Employer Identification No.)
incorporation or organization)

9620 Medical Center Drive, Suite 300

Rockville, Maryland

(Address of principal executive offices)

20850

(Zip code)

(240) 864-2600

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES x NO ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

YES x NO ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨

Accelerated filer ¨

Non-accelerated filer þ

Smaller reporting company þ

Emerging growth

company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ¨ NO x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the most recent practicable date.

Class		Outstanding at November 7, 2018
Common Stock $.01 Par Value		93,587,515

CASI PHARMACEUTICALS, INC.

Table of Contents

	PAGE

PART I. FINANCIAL INFORMATION

Item 1 — Consolidated Financial Statements

Condensed Consolidated Balance Sheets as of September 30, 2018 (unaudited) and December 31, 2017	4

Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2018 and 2017 (unaudited)	5

Condensed Consolidated Statement of Stockholders’ Equity for the Nine Months Ended September 30, 2018 (unaudited)	6

Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2018 and 2017 (unaudited)	7

Notes to Condensed Consolidated Financial Statements (unaudited)	8

Item 2 — Management’s Discussion and Analysis of Financial Condition and Results of Operations	18

Item 3 — Quantitative and Qualitative Disclosures About Market Risk	27

Item 4 — Controls and Procedures	27

Part II. OTHER INFORMATION

Item 1 — Legal Proceedings	27

Item 1A — Risk Factors	27

Item 2 — Unregistered Sales of Equity Securities and Use of Proceeds	28

Item 3 — Defaults Upon Senior Securities	28

Item 4 — Removed and Reserved	28

Item 5 — Other Information	28

Item 6 — Exhibits	28

EXHIBIT INDEX	29

SIGNATURES	30

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements also may be included in other statements that we make. All statements that are not descriptions of historical facts are forward-looking statements. These statements can generally be identified by the use of forward-looking terminology such as “believes,” “expects,” “intends,” “may,” “will,” “should,” or “anticipates” or similar terminology. These forward-looking statements include, among others, statements regarding the timing of our clinical trials, our cash position and future expenses, and our future revenues.

Our forward-looking statements are based on information available to us today, and we will not update these statements. Actual results could differ materially from those currently anticipated due to a number of factors, including: risks relating to interests of our largest stockholders that differ from our other stockholders; the difficulty of executing our business strategy in China; the risk that we will not be able to effectively select, register and commercialize products from our recently acquired portfolio of abbreviated new drug applications (ANDAs); our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the China Food and Drug Administration authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; the volatility in the market price of our common stock; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; risk that results in preclinical and early clinical models are not necessarily indicative of later clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; and our dependence on third parties. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission (“SEC”), which are available at www.sec.gov.

PART I. FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

CASI Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

	September 30, 2018			December 31, 2017
	(Unaudited)			(Note 1)
ASSETS
Current assets:
Cash and cash equivalents	$	98,867,087		$	43,489,935
Investments, at fair value		1,165,046			-
Prepaid expenses and other		1,343,667			322,493
Total current assets		101,375,800			43,812,428

Property and equipment, net		1,594,189			1,046,514
Other assets		228,431			242,023
Intangible assets, net		17,110,422			-
Total assets	$	120,308,842		$	45,100,965

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	1,740,611		$	2,087,770
Payable to related parties		2,880,000			2,228,366
Accrued liabilities		800,975			745,961
Note payable, net of discount		1,499,285			-
Total current liabilities		6,920,871			5,062,097

Note payable, net of discount		-			1,498,754
Other liabilities		66,567			-
Total liabilities		6,987,438			6,560,851

Commitments and contingencies

Stockholders' equity:
Preferred stock, $1.00 par value: 5,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2018 and December 31, 2017		-			-
Common stock, $.01 par value: 170,0000,000 shares authorized at September 30, 2018 and December 31, 2017; 93,480,493 shares and 69,901,625 shares issued at September 30, 2018 and December 31, 2017, respectively		934,804			699,015
Common stock to be issued for 186,567 shares		1,000,000			-
Additional paid-in capital		590,322,314			498,577,372
Treasury stock, at cost: 79,545 shares held at September 30, 2018 and December 31, 2017		(8,034,244	)		(8,034,244	)
Accumulated other comprehensive loss		(1,224,748	)		-
Accumulated deficit		(469,676,722	)		(452,702,029	)
Total stockholders' equity		113,321,404			38,540,114
Total liabilities and stockholders' equity	$	120,308,842		$	45,100,965

See accompanying condensed notes.

CASI Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

	Three Months Ended						Nine Months Ended
	September 30, 2018			September 30, 2017			September 30, 2018			September 30, 2017
Revenues:
Product sales	$	-		$	-		$	-		$	-

Costs and expenses:
Research and development		1,806,222			970,989			5,232,925			3,747,683
General and administrative		6,904,800			625,878			12,250,269			1,961,463
Acquired in-process research and development		-			-			686,998			-
		8,711,022			1,596,867			18,170,192			5,709,146

Interest (income) expense, net		(10,652	)		546			(30,453	)		476
Other expense		55,941			-			67,266			-
Change in fair value of contingent rights		-			16,110			-			12,665

Net loss	$	(8,756,311	)	$	(1,613,523	)	$	(18,207,005	)	$	(5,722,287	)

Net loss per share (basic and diluted)	$	(0.10	)	$	(0.03	)	$	(0.22	)	$	(0.10	)
Weighted average number of common shares outstanding (basic and diluted)		86,953,611			60,196,574			81,457,085			60,196,574

Comprehensive loss:
Net loss	$	(8,756,311	)	$	(1,613,523	)	$	(18,207,005	)	$	(5,722,287	)
Foreign currency translation adjustment		(685,106	)		-			(1,224,748	)		-
Total comprehensive loss	$	(9,441,417	)	$	(1,613,523	)	$	(19,431,753	)	$	(5,722,287	)

See accompanying condensed notes.

CASI Pharmaceuticals, Inc.

Condensed Consolidated Statement of Stockholders’ Equity

(Unaudited)

	Preferred Stock				Common Stock				Treasury			Additional Paid-in			Common Stock to Be		Accumulated Other Comprehensive			Accumulated
	Shares		Amount		Shares		Amount		Stock			Capital			Issued		Loss			Deficit			Total
Balance at December 31, 2017		-	$	-		69,822,080	$	699,015	$	(8,034,244	)	$	498,577,372				$	-		$	(452,702,029	)	$	38,540,114
Cumulative effect adjustment due to the adoption of ASU 2016-01		-		-		-		-		-			-			-		-			1,232,312			1,232,312
Issuance of common stock and warrants pursuant to financing agreements		-		-		22,385,038		223,850		-			86,766,366			-		-			-			86,990,216
Issuance of common stock for options exercised		-		-		139,683		1,397		-			256,551			-		-			-			257,948
Stock option grants surrendered		-		-		-		-		-			(117,194	)		-		-			-			(117,194	)
Issuance of common stock from exercise of warrants		-		-		1,054,147		10,542		-			2,077,493			-		-			-			2,088,035
Common stock to be issued		-		-		-		-		-			-			1,000,000		-			-			1,000,000
Stock issuance costs		-		-		-		-		-			(755,767	)		-		-			-			(755,767	)
Stock-based compensation expense		-		-		-		-		-			3,517,493			-		-			-			3,517,493
Foreign currency translation adjustment		-		-		-		-		-			-			-		(1,224,748	)		-			(1,224,748	)
Net loss		-		-		-		-		-			-			-		-			(18,207,005	)		(18,207,005	)
Balance at September 30, 2018		-	$	-		93,400,948	$	934,804	$	(8,034,244	)	$	590,322,314		$	1,000,000	$	(1,224,748	)	$	(469,676,722	)	$	113,321,404

See accompanying condensed notes.

CASI Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Nine Months Ended
	September 30, 2018			September 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(18,207,005	)	$	(5,722,287	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		249,738			69,420
Loss on disposal of assets		5,427
Amortization of intangible assets		944,563			-
Stock-based compensation expense		3,517,493			516,237
Acquired in-process research and development		686,998			-
Unrealized loss on equity investment		67,266			-
Non-cash interest		531			5,607
Change in fair value of contingent rights		-			12,665
Changes in operating assets and liabilities:
Prepaid expenses and other		(610,795	)		(119,686	)
Accounts payable		(326,535	)		139,339
Payable to related party		651,634			-
Accrued liabilities		146,149			51,694
Net cash used in operating activities		(12,874,536	)		(5,047,011	)

CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of furniture and equipment		599			-
Purchases of property and equipment		(861,667	)		(405,849	)
Acquisition of Abbreviated New Drug Applications and related items		(19,171,956	)		-
Net cash used in investing activities		(20,033,024	)		(405,849	)

CASH FLOWS FROM FINANCING ACTIVITIES
Stock issuance costs		(755,767	)		-
Proceeds from sale of common stock and warrants		86,990,216			-
Proceeds from sale of common stock to be issued		1,000,000			-
Proceeds from exercise of stock options		257,948			-
Cash paid to satisfy tax withholding obligations		(117,194	)		-
Proceeds from exercise of stock warrants		2,088,035			-
Net cash provided by financing activities		89,463,238			-

Effect of exchange rate changes on cash and cash equivalents		(1,178,526	)		-
Net increase (decrease) in cash and cash equivalents		55,377,152			(5,452,860	)
Cash and cash equivalents at beginning of period		43,489,935			27,092,928
Cash and cash equivalents at end of period	$	98,867,087		$	21,640,068

See accompanying condensed notes.

CASI Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

September 30, 2018 (unaudited)

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of CASI Pharmaceuticals, Inc. and its subsidiaries (“CASI” or “the Company”), Miikana Therapeutics, Inc. (“Miikana”) and CASI Pharmaceuticals (Beijing) Co., Ltd. (“CASI China”). The Company previously operated under a different name prior to restructuring its business in 2012 in connection with an investment led by one of the Company’s largest stockholders. CASI China is a non-stock Chinese entity with 100% of its interest owned by CASI. CASI China received approval for a business license from the Beijing Industry and Commercial Administration in August 2012 and has operating facilities in Beijing. All inter-company balances and transactions have been eliminated in consolidation.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, such condensed consolidated financial statements do not include all of the information and disclosures required by U.S. generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. The accompanying December 31, 2017 financial information was derived from the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Operating results for the three and nine month periods ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or any other future period. For further information, refer to the Company’s audited consolidated financial statements and footnotes thereto included in its Form 10-K for the year ended December 31, 2017.

Liquidity Risks and Management’s Plans

Additionally, in March 2018, the Company entered into securities purchase agreements pursuant to which the Company issued 15,432,091 shares of its common stock with accompanying warrants to purchase 6,172,832 shares of its common stock and received $50 million in gross proceeds in a private placement (the “March 2018 Financing”). The March 2018 Financing closing included an investment from ETP Global Fund, L.P., a healthcare investment fund. The managing member of Emerging Technology Partners, LLC, which is the general partner of ETP Global Fund, L.P., is also the Executive Chairman of the Company. The March 2018 Financing also included an investment from IDG-Accel China Growth Fund III L.P. (“IDG-Accel Growth”) and IDG-Accel China III Investors L.P. (“IDG-Accel Investors”). A director and shareholder of IDG-Accel China Growth Fund GP III Associates Ltd., which is the ultimate general partner of IDG-Accel Growth and IDG-Accel Investors, is also a member of the Company’s Board of Directors. Net proceeds from the September 2018 Closing, the October 2018 Closing, and the March 2018 Financing are being used to prepare for the anticipated launch of the Company’s first commercial product in China, to support the Company’s business development activities, to advance the development of the Company’s pipeline, to support its marketing and commercial planning activities, and for other general corporate purposes.

Acquisition of Abbreviated New Drug Applications

On January 26, 2018, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Sandoz, Inc. (“Sandoz”). Pursuant to the Asset Purchase Agreement, the Company acquired a portfolio of 29 abbreviated new drug applications (“ANDAs”), including 25 ANDAs approved by the U.S. Food and Drug Administration (“FDA”) and four pipeline ANDAs that are pending FDA approval, limited quantities of certain active pharmaceutical ingredient (“API”), and certain manufacturing and other information related to the products (collectively, the ANDAs, API and other information are referred to as the “Acquired Assets”). To facilitate the sale and transition, the parties also entered into several limited term ancillary arrangements.

The Acquired Assets enhance the Company’s strategic focus to build a robust pipeline and commercialize quality drug candidates in China. The Company intends to select and commercialize certain products from the portfolio that have unique market and cost-effective manufacturing opportunities in China (and potentially in the U.S.).

The total purchase price for the Acquired Assets was $18.0 million in cash. The Company accounted for the purchase of the Acquired Assets as an asset acquisition (consisting of a concentrated group of similar identifiable assets, including ANDAs and API) following the guidance contained in Accounting Standards Update (“ASU”) 2017-01. The total purchase price, along with approximately $1.2 million of transaction expenses, was allocated to the Acquired Assets based on their relative fair values, as follows:

ANDAs	$	18,608,000
API		564,000
Total value	$	19,172,000

Of the total value allocated to the ANDAs, approximately $553,000 was immediately expensed as acquired in-process research and development since the underlying ANDAs have not been approved by the FDA, and of the total value allocated to the API, approximately $134,000 was immediately expensed as acquired in-process research and development since the Company does not intend to use all of the API. The allocated cost of the capitalized ANDAs will be amortized over their estimated useful lives of 13 years. The capitalized API will be expensed in the period it is used or if its value is otherwise impaired.

The fair values of certain acquired ANDAs were estimated using the discounted cash flow method (an income approach), which involves the use of Level 3 inputs such as estimates for projected sales, expenses, and cash flows, estimates of total addressable markets and market penetration rates, future sales growth and inflation rates, expected income and value-added tax rates, and a required rate of return adjusted for both industry and Company-specific risks, among other inputs. The fair values of the remaining ANDAs were estimated using a multiple of values method (an income approach), which involved using Level 3 inputs such as estimated addressable markets and market penetration rates. The fair value of the API was estimated using Level 2 inputs, such as quoted market prices for similar API from various suppliers or other sources. The ANDAs will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable; no such triggering events were identified during the period from the date of acquisition to September 30, 2018.

Intangible Assets

Intangible assets were acquired as part of the 2018 asset acquisition from Sandoz and include ANDAs for a total of 25 previously marketed generic products. These intangible assets were originally recorded at relative fair values based on the purchase price for the asset acquisition and are stated net of accumulated amortization.

The ANDAs are being amortized over their estimated useful lives of 13 years, using the straight-line method. Management reviews finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, in a manner similar to that for property and equipment. No impairment losses related to intangible assets were recognized in the nine months ended September 30, 2018.

As discussed in Note 2, in January 2018, the Company purchased the Acquired Assets from Sandoz for a total purchase price of $18.0 million. The total purchase price, along with transaction expenses of approximately $1.2 million, was allocated to the ANDAs and API acquired based on their relative fair values. Net finite-lived intangible assets at September 30, 2018 consists of the following:

Asset		Gross Value				Accumulated Amortization				Estimated useful lives
ANDAs		$	18,054,985			$	(944,563	)		13 years

Expected future amortization expense is as follows for the years ending December 31:

2018 (remaining three months)	$	347,212
2019		1,388,845
2020		1,388,845
2021		1,388,845
2022		1,388,845
2023 and thereafter		11,207,830

Foreign Currency Translation

The U.S. dollar is the reporting currency of the Company. Foreign currency denominated assets and liabilities of the Company and its foreign subsidiary are translated into U.S. dollars. Accordingly, assets and liabilities are translated using the exchange rates in effect at the consolidated balance sheet date and revenues and expenses at the rates of exchange prevailing when the transactions occurred, using an average periodic exchange rate. In 2017, remeasurement adjustments were included in income (loss). As discussed in Note 2, on January 26, 2018, the Company acquired a portfolio of ANDAs. Management believes that this transaction provides significant and permanent changes to its operations in China, and that it may allow its subsidiary in China to generate operating revenues from the China marketplace in the future and potentially sustain its own operations without the necessity of parent support. Accordingly, effective January 1, 2018, the functional currency of the Company’s subsidiary based in China has been changed to the local currency of the China Renminbi (“RMB”). The change in functional currency did not have a material impact on the consolidated financial statements.

Beginning January 1, 2018, translation gains and losses relating to the financial statements of the Company’s China subsidiary are included as accumulated other comprehensive loss in the accompanying Condensed Consolidated Balance Sheets.

Investments

The Company has an equity investment in the publicly traded common stock of a company. Beginning on January 1, 2018 with the adoption of ASU 2016-01, the Company’s investment in this equity security is considered a trading security and is carried at its estimated fair value, with changes in fair value reported in the statement of operations each reporting period. The fair value of this security was measured using its quoted market price, a Level 1 input, and was approximately $1.2 million as of September 30, 2018.

In January 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-01, “Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.” In February 2018, the FASB issued ASU 2018-03, “Technical Corrections and Improvements to Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.” The accounting standards primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, it includes a clarification related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2017. The Company adopted ASU 2016-01 and ASU 2018-03 on January 1, 2018 and recorded a cumulative effect adjustment that decreased accumulated deficit by approximately $1.2 million. Effective January 1, 2018, the adoption date, changes in the fair value of the Company’s investments in equity securities are recognized in the statements of operations and comprehensive loss.

Inventories

Inventories consist of raw materials and are stated at the lower of cost or net realizable value. Cost is determined using a first-in, first-out method. The carrying value of raw materials inventory was approximately $430,000 as of September 30, 2018 and is included in “prepaid expenses and other assets” in the accompanying condensed consolidated balance sheets.

Research and Development

License Arrangements

The Company has certain product rights and perpetual exclusive licenses from Spectrum Pharmaceuticals, Inc. and certain of its affiliates (together referred to as “Spectrum”) to develop and commercialize the following commercial oncology drugs and drug candidates in the greater China region (which includes China, Taiwan, Hong Kong and Macau) (the “Territories”):

EVOMELA^® (melphalan) for Injection (“EVOMELA”);

MARQIBO^® (vinCRIStine sulfate LIPOSOME injection) (“MARQIBO”); and

ZEVALIN^® (ibritumomab tiuxetan) (“ZEVALIN”).

CASI is responsible for developing and commercializing these three drugs in the Territories, including the submission of import drug registration applications and conducting confirmatory clinical trials as needed.

The Company is in various stages of the regulatory and development process to obtain marketing approval for EVOMELA^®, MARQIBO^®, and ZEVALIN^® in its territorial region, with ZEVALIN^® commercially available in Hong Kong. In January 2016, the China Food and Drug Administration (CFDA) accepted for review the Company’s import drug registration application for MARQIBO^® and has completed the quality testing phase of the regulatory process and is currently in technical review by Center for Drug Evaluation (CDE) of the CFDA as part of the regulatory process. On March 10, 2016, Spectrum received notification from the FDA of the grant of approval of its New Drug Application (NDA) for EVOMELA^® primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. In December 2016, the CFDA accepted for review the Company’s import drug registration application for EVOMELA^® and in 2017 has granted priority review of the import drug registration clinical trial application (CTA). EVOMELA^® has completed the quality testing phase of the regulatory process, as well as the technical review by CDE of the CFDA, and was evaluated under a CFDA CDE Advisory Committee meeting held in the second quarter of 2018 followed by a series of standard questions from the CFDA related to EVOMELA^® drug product production which usually reflects the final stage of CFDA assessment before approval based on the Import Drug Approval registration pathway. CASI is diligently working with Spectrum and their vendors to address the questions and submit the requested documents. In 2017, the CFDA accepted for review the Company’s import drug registration for ZEVALIN^® including both the antibody kit and the radioactive Yttrium-90 component. ZEVALIN^® is currently under the quality testing phase of the regulatory process by National Institute for Food and Drug Control (NIFDC) as well as the technical review by CDE of the CFDA.

Note Payable

As part of the license arrangements with Spectrum (see Note 8), the Company issued to Spectrum a $1.5 million 0.5% secured promissory note originally due March 17, 2016, which was subsequently amended and extended to September 17, 2019. All other terms remain the same. The promissory note was recorded initially at its fair value, giving rise to a discount of approximately $136,000; the promissory note is presented as note payable, net of discount in the accompanying condensed consolidated balance sheets. For the nine months ended September 30, 2018 and 2017, the Company recognized $531 and $5,607 of non-cash interest expense, respectively, related to the amortization of the debt discount, using the effective interest rate method.

10.

Stockholders’ Equity

Securities Purchase Agreements

As described in Note 1, in September 2018, the Company entered into securities purchase agreements the (“Securities Purchase Agreements”) with certain institutional investors, accredited investors and current stockholders, pursuant to which the Company agreed to sell 9,048,504 shares of its common stock with accompanying warrants to purchase 2,714,548 shares of its common stock in a $48.5 million private placement. The purchase price for each share of common stock and warrant was $5.36. The warrants will become exercisable on March 23, 2019 at a $7.19 per share exercise price and will expire on September 24, 2021. On September 24, 2018, the Company completed its initial closing, the September 2018 Closing, and issued 6,809,699 shares of its common stock with accompanying warrants to purchase 2,042,907 shares of its common stock and received $36.5 million in gross proceeds. The fair value of the warrants issued is $6,087,863, or $2.98 per warrant, calculated using the Black-Scholes-Merton valuation model with a contractual life of 3 years, an assumed volatility of 88.39%, and a risk-free interest rate of 2.89%. On October 10, 2018, the Company completed its second closing, the October 2018 Closing, on an additional $1 million in gross proceeds, which was received in September 2018 and reflected as “common stock to be issued” on the accompanying condensed consolidated balance sheet as of September 30, 2018. The Company expects to close on the remaining $11 million. The Securities Purchase Agreements and warrants each include additional customary representations, warranties and covenants. The Company also agreed to file a resale registration within 120 days following the closing covering the shares of common stock issued and the shares of common stock underlying the warrants.

The Company’s Executive Chairman, and the Company’s Chief Executive Officer played a key role in identifying and securing potential investors for the September 2018 Financing. As a result, the Company did not have to pay a commission to, or incur additional expenses for, a placement agent. In exchange for their services, which were deemed to be outside the scope of their responsibilities as officers and directors of the Company, the Company’s Audit Committee approved payments of $1,460,000 and $480,000 to the Executive Chairman and the Chief Executive Officer, respectively. As of September 30, 2018, $1,380,000 and $120,000 of these payments, respectively, have been earned and are included as general and administrative expenses in the accompanying condensed consolidated statement of operations for the three and nine month periods ended September 30, 2018. The amount payable to the Executive Chairman totaling $1,380,000 is included in “payable to related parties” in the accompanying condensed consolidated balance sheet as of September 30, 2018 and was paid in October 2018.

As described in Note 1, in March 2018, the Company entered into securities purchase agreements with certain institutional investors, accredited investors and current stockholders, pursuant to which the Company issued 15,432,091 shares of its common stock with accompanying warrants to purchase 6,172,832 shares of its common stock and received $50 million in gross proceeds in a private placement. The purchase price for each share of common stock and warrant was $3.24. The warrants became exercisable on September 17, 2018 at a $3.69 per share exercise price and will expire on March 21, 2023. The fair value of the warrants issued is $15,062,000, or $2.44 per warrant, calculated using the Black-Scholes-Merton valuation model with a contractual life of 5 years, an assumed volatility of 75.4%, and a risk-free interest rate of 2.69%. The securities purchase agreements and warrants each include additional customary representations, warranties and covenants. The Company filed a resale registration covering the shares of common stock issued and the shares of common stock underlying the warrants on Form S-3 (File No. 333-226206) which became effective on August 8, 2018.

Common Stock Sales Agreement

On February 23, 2018, the Company entered into a Common Stock Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“HCW”). Pursuant to the terms of the Sales Agreement, the Company may sell from time-to-time, at its option, shares of the Company’s common stock through HCW, as sales agent, with an aggregate sales price of up to $25 million (the “Shares”).

Any sales of Shares pursuant to the Sales Agreement will be made under the Company’s effective “shelf” registration statement (the “Registration Statement”) on Form S-3 (File No. 333-222046) which became effective on December 22, 2017 and the related prospectus supplement and the accompanying prospectus, as filed with the Securities and Exchange Commission (the “SEC”) on February 23, 2018.

In March 2018, the Company issued 143,248 Shares under the Sales Agreement resulting in net proceeds to the Company of approximately $475,000. As of September 30, 2018, approximately $24.5 million remained available under the Sales Agreement.

11.

Net Loss Per Share

Net loss per share (basic and diluted) was computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding. Outstanding stock options and warrants totaling 18,384,932 and 13,425,608 as of September 30, 2018, respectively, were anti-dilutive and, therefore, were not included in the computation of weighted average shares used in computing diluted loss per share.

12.

Stock-Based Compensation and Warrants

The Company has adopted incentive and nonqualified stock option plans for executive, scientific and administrative personnel of the Company as well as outside directors and consultants. In June 2018, the Company’s stockholders approved an amendment to the 2011 Long-Term Incentive Plan, increasing the number of shares of common stock reserved for issuance from 14,230,000 to 20,230,000 to be available for grants and awards. As of September 30, 2018, there are 18,384,932 shares issuable under options previously granted and currently outstanding, with exercise prices ranging from $0.86 to $8.23. Options granted under the plans generally vest over periods varying from immediately to one to five years, are not transferable and generally expire ten years from the date of grant. As of September 30, 2018, 6,878,610 shares remained available for grant under the Company’s 2011 Long-Term Incentive Plan. On March 13, 2018, upon the recommendation of the Compensation Committee of the Board of Directors (the “Board”), the Board approved a grant of stock options to the Company’s Executive Chairman exercisable for 1 million shares of common stock that will vest and become exercisable on the first anniversary date of the grant. In addition, the Board approved the grant of a performance-based option covering 4 million shares of common stock that will vest if, within 18 months of the date of grant, specific operational and strategic milestones are achieved. Both grants were approved by the Company’s stockholders at the 2018 Annual Meeting of Stockholders.

The Company records compensation expense associated with stock options and other equity-based compensation in accordance with provisions of authoritative guidance. Compensation costs are recognized over the requisite service period, which is generally the option vesting term of up to five years. Awards with performance conditions are expensed when it is probable that the performance condition will be achieved. There was minimal expense recorded for share awards with performance conditions during the nine months ended September 30, 2018 and 2017.

The Company’s net loss for the nine months ended September 30, 2018 and 2017 includes $3,517,493 and $516,237, respectively, of non-cash compensation expense related to the Company’s share-based compensation awards. The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense, as follows:

	Nine Month Period ended September 30,
	2018		2017
Research and development	$	232,230	$	225,342
General and administrative		3,285,263		290,895
Share-based compensation expense	$	3,517,493	$	516,237
Net share-based compensation expense, per common share:
Basic and diluted	$	0.04	$	0.01

The Company uses the Black-Scholes-Merton valuation model to estimate the fair value of service based and performance-based stock options granted to employees. Option valuation models, including Black-Scholes-Merton, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award. Following are the weighted-average assumptions used in valuing the stock options granted to employees during the nine-month periods ended September 30, 2018 and 2017:

	Nine Month Period ended September 30,
	2018			2017
Expected volatility		78.79	%		78.92	%
Risk free interest rate		2.80	%		1.97	%
Expected term of option		5.77 years			6.34 years
Expected dividend yield		0.00	%		0.00	%

The weighted average fair value of stock options granted during the nine-month periods ended September 30, 2018 and 2017 were $4.51 and $0.73, respectively.

A summary of the Company's stock option plans and of changes in options outstanding under the plans during the nine-month period ended September 30, 2018 is as follows:

	Number of Options			Weighted Average Exercise Price
Outstanding at January 1, 2018		11,585,315		$	1.42
Exercised		(156,283	)	$	1.65
Granted		7,286,000		$	4.02
Expired		(279,970	)	$	1.50
Forfeited		(50,130	)	$	3.28
Outstanding at September 30, 2018		18,384,932		$	2.44
Exercisable at September 30, 2018		8,753,696		$	1.59

Cash received from option exercises under all share-based payment arrangements for the nine months ended September 30, 2018 was $257,948. There were no option exercises during the nine months ended September 30, 2017.

Warrants

Warrants issued generally expire after 2-5 years from the date of issuance. Stock warrant activity is as follows:

	Number of Warrants			Weighted Average Exercise Price
Outstanding at January 1, 2018		6,264,016		$	2.23
Issued		8,215,739		$	4.56
Exercised		(1,054,147	)	$	1.98
Expired		-		$	-
Outstanding at September 30, 2018		13,425,608		$	3.68
Exercisable at September 30, 2018		11,382,701		$	3.04

Cash received from warrants exercised during the nine months ended September 30, 2018 was $2,088,035. There were no warrants exercised during the nine months ended September 30, 2017.

13.

Income Taxes

At December 31, 2017, the Company had a $3.2 million unrecognized tax benefit. The Company recorded a full valuation allowance on the net deferred tax asset recognized in the consolidated financial statements as of December 31, 2017.

During the nine months ended September 30, 2018, there were no material changes to the measurement of unrecognized tax benefits in various taxing jurisdictions. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense.

The tax returns for all years in the Company’s major tax jurisdictions are not settled as of September 30, 2018. Due to the existence of tax attribute carryforwards (which are currently offset by a full valuation allowance), the Company treats all years’ tax positions as unsettled due to the taxing authorities’ ability to modify these attributes.

14.

Related Party Transactions

The Company has supply agreements with Spectrum for the purchase of EVOMELA^®, MARQIBO^®, and ZEVALIN^® in China for quality testing purposes to support CASI’s application for import drug registration and for commercialization purposes. The former CEO of Spectrum is also a member of CASI’s Board and Spectrum is the Company’s largest shareholder. All amounts payable to Spectrum for material purchases have been paid as of September 30, 2018. There were no materials purchased from Spectrum for the nine months ended September 30, 2018. In April and June 2017, under supply agreements with Spectrum, the Company received shipments of EVOMELA^® and MARQIBO^®, respectively, in China for quality testing purposes to support CASI’s application for import drug registration. The total cost of the materials was approximately $477,000, which is included in research and development expense for the nine months ended September 30, 2017.

Emerging Technology Partners, LLC (“ETP”) incurred approximately $3 million of expenses for due diligence and related services (the “Services”) for certain business development activities. The Company benefited by having access to the results of those Services and did not have to incur such expense on its own. The Company’s Executive Chairman is the founder and managing member of ETP. The Company’s Audit Committee authorized and directed the Company to reimburse ETP $1.5 million for the expenses incurred in connection with the Services which is included as general and administrative expenses in the accompanying condensed consolidated statement of operations for the three and nine month periods ended September 30, 2018. The amount payable to ETP totaling $1.5 million is included in “payable to related parties” in the accompanying condensed consolidated balance sheet as of September 30, 2018 and was paid in October 2018.

15.

New Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 supersedes existing lease guidance, including Accounting Standards Codification (ASC) 840 - Leases. Among other things, the new standard requires recognition of a right-of-use asset and liability for future lease payments for contracts that meet the definition of a lease. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted. The standard must be applied using a modified retrospective approach. The Company is completing its evaluation of the effect of the adoption of this ASU and tentatively expects that the adoption will result in an increase to both assets and liabilities on the consolidated balance sheet, with no significant effects on operating results.

In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842) Targeted Improvements, which offers a transition option to entities adopting the new lease standard. Under the transition option, entities can recognize a cumulative effect adjustment to the opening balance of retained earnings of the year in which the new lease standard is adopted, rather than in the earliest period presented in their financial statements. The Company is currently evaluating the effect the adoption of this ASU will have on its consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-01, Clarifying the Definition of a Business (Topic 805). The amendments in the update provide a screen to determine when a set is not a business. If the screen is not met, the amendments in the update (1) require that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. The amendments provide a framework to assist entities in evaluating whether both an input and a substantive process are present. Lastly, the amendments in the update narrow the definition of the term output so that the term is consistent with how outputs are described in Topic 606. The ASU is effective for annual periods and interim periods within those annual periods beginning after December 15, 2017; earlier adoption is permitted under certain criteria. The Company adopted this ASU on January 1, 2018. While this ASU did not have a material effect on the Company’s financial statements on the date of adoption, the Company did follow the new guidance in determining that its acquisition of ANDAs from Sandoz, Inc. in January 2018 was an asset acquisition (see Note 2).

In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting. ASU 2017-09 provides clarification on when modification accounting should be used for changes to the terms or conditions of a share-based payment award. This ASU does not change the accounting for modifications but clarifies that modification accounting guidance should only be applied if there is a change to the value, vesting conditions, or award classification and would not be required if the changes are considered non-substantive. This ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted ASU 2017-09 in the first quarter of 2018 and the adoption of this ASU did not have a material effect on the consolidated financial statements.

In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting which includes updated guidance for share-based payment awards issued to non-employees. The updated standard aligns the accounting for share-based payment awards for non-employees with employees, except for guidance related to the attribution of compensation costs for non-employees. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods for public business entities, with early adoption permitted. The Company is considering early adopting this standard in the fourth quarter of 2018. The adoption of this ASU is not expected to have a material impact on the Company’s consolidated financial statements.

There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows.

16.

Commitments

In 2018, the Company entered into purchase obligation commitments for EVOMELA^®from Spectrum for approximately $9.2 million.

In April 2018, the Company entered into a lease agreement for office space in China that continues through April 2021. Future minimum lease payments are approximately $139,300 in 2018, $557,200 in 2019, $557,200 in 2020 and $139,300 in 2021.

In October 2018, the Company entered into a lease agreement for office space in China that continues through November 2021. Future minimum lease payments are approximately $90,600 in 2018, $418,000 in 2019, $418,000 in 2020 and $383,100 in 2021.

In October 2018, the Company amended the lease for its principal executive offices in Rockville, MD, effective November 1, 2018 to increase the total space covered under the lease to 6,068 square feet. The Company also extended the lease term from December 31, 2019 to July 31, 2022. Incremental future minimum lease payments associated with the amendment are approximately $8,400 in 2018, $50,500 in 2019, $138,600 in 2020, $142,700 in 2021 and $85,700 in 2022.

17.

Subsequent Event

In October 2018, the Company entered into an agreement with Laurus Labs Limited (“Laurus”), a company organized under the Laws of India, pursuant to which the Company will acquire from Laurus one U.S. FDA-approved abbreviated new drug application for tenofovir disoproxil fumarate (TDF ANDA), which is indicated for the treatment of hepatitis B virus. The aggregate purchase price for the TDF ANDA was $3 million, with an upfront payment of $700,000, paid in October 2018, and $2.3 million to be paid upon completion of certain milestones.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

OVERVIEW

We are a U.S. based biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world. We intend to execute our plan to become a leading pharmaceutical company with a substantial market share in China. We are headquartered in Rockville, Maryland and have a wholly owned subsidiary and R&D operations in Beijing, China.

Our product pipeline features the following: (1) EVOMELA^®, MARQIBO^®, and ZEVALIN^®, all U.S. FDA approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for China regional rights, and currently in various stages in the regulatory process for market approval in China, and (2) an acquired portfolio of 25 FDA-approved abbreviated new drug applications (“ANDAs”) and four pipeline ANDAs that are pending FDA approval, from which we will prioritize a select subset for product registration and commercialization in China. The Company also recently announced entering into an agreement with Laurus Labs Limited to purchase an ANDA for tenofovir disoproxil fumarate (TDF) indicated for hepatitis B virus. In addition to these advanced products, our pipeline includes a proprietary Phase 2 drug candidate, ENMD-2076, that the Company has determined not to pursue as a single agent and is exploring feasibility of combination as a clinical strategy, and also CASI-001 and CASI-002, proprietary early-stage candidates in immuno-oncology in preclinical development.

We believe our pipeline reflects a risk-balanced approach between products in various stages of development, and between products that we develop ourselves and those that we develop with our partners for the China regional market. We intend to continue building a significant product pipeline of high quality, cost-effective pharmaceuticals, as well as innovative drug candidates that we will commercialize alone in China and with partners for the rest of the world. For in-licensed products, the Company uses a market-oriented approach to identify pharmaceutical candidates that it believes have the potential for gaining widespread market acceptance, either globally or in China, and for which development can be accelerated under the Company’s drug development strategy. For our FDA-approved ANDAs, we intend to select and commercialize certain products from the portfolio that offer unique market and cost-effective manufacturing opportunities in China and/or in the U.S.

Our primary research and development focus is to acquire high quality, cost-effective medicines, as well as to in-license clinical-stage and late-stage drug candidates so that we can immediately employ our U.S. and China drug development model to accelerate commercialization, and clinical and regulatory progress. In addition to our high quality, cost-effective medicines, and our clinical-and late-stage approach for innovative products, we have other potential drug candidates in preclinical development which we will continue to evaluate through 2018 and 2019. The implementation of our plans will include leveraging our resources in both the United States and China. In order to capitalize on the drug development and capital resources available in China, we are doing business in China through our wholly-owned China-based subsidiary that will execute the China portion of our drug development strategy, including conducting clinical trials in China, pursuing local funding opportunities and strategic collaborations, and implementing our transition to a commercial enterprise.

Since inception, the Company has incurred significant losses from operations and has incurred an accumulated deficit of $469.7 million. The Company restructured its business in 2012 in connection with an investment led by one of the Company’s largest stockholders, followed by implementation of a name change to reflect its core mission and business strategy. The Company expects to continue to incur operating losses for the foreseeable future due to, among other factors, its continuing clinical and development activities. In September 2018, the Company entered into securities purchase agreements with certain institutional investors, accredited investors and current stockholders, pursuant to which the Company agreed to sell 9,048,504 shares of its common stock with accompanying warrants to purchase 2,714,548 shares of its common stock in a $48.5 million private placement (the “September 2018 Financing”). The Company held its initial closing on September 24, 2018 (the “September 2018 Closing”) and second closing on October 10, 2018 (the “October 2018 Closing”). The Company has received gross proceeds of $37.5 million and expects to receive additional gross proceeds of $11 million. Additionally, in March 2018, the Company entered into securities purchase agreements pursuant to which the Company issued 15,432,091 shares of its common stock with accompanying warrants to purchase 6,172,832 shares of its common stock and received $50 million in gross proceeds in a private placement (the “March 2018 Financing”). The March 2018 Financing closing included an investment from ETP Global Fund, L.P., a healthcare investment fund. The managing member of Emerging Technology Partners, LLC, which is the general partner of ETP Global Fund, L.P., is also the Executive Chairman of the Company. The March 2018 Financing also included an investment from IDG-Accel China Growth Fund III L.P. (“IDG-Accel Growth”) and IDG-Accel China III Investors L.P. (“IDG-Accel Investors”). A director and shareholder of IDG-Accel China Growth Fund GP III Associates Ltd., which is the ultimate general partner of IDG-Accel Growth and IDG-Accel Investors, is also a member of the Company’s Board of Directors. Net proceeds from the September 2018 Closing, the October 2018 Closing, and the March 2018 Financing are being used to prepare for the anticipated launch of the Company’s first commercial product in China, to support the Company’s business development activities, to advance the development of the Company’s pipeline, to support its marketing and commercial planning activities, and for other general corporate purposes.

As a result of the September 2018 Closing, October 2018 Closing, and the March 2018 Financing, the Company believes that it has sufficient resources to fund its operations at least through November 14, 2019. As of September 30, 2018, approximately $15.2 million of the Company’s cash balance was held by CASI China. We intend to continue to exercise tight controls over operating expenditures. In developing drug candidates, we intend to use and leverage resources available to us in both the United States and China. We intend to pursue additional financing opportunities as well as opportunities to raise capital through forms of non- or less-dilutive arrangements, such as partnerships and collaborations with organizations that have capabilities and/or products that are complementary to our capabilities and products in order to continue the development of our product candidates that we intend to pursue to commercialization.

Additional funds raised by issuing equity securities may result in dilution to existing stockholders.

CRITICAL ACCOUNTING POLICIES AND THE USE OF ESTIMATES

The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Our critical accounting policies, including the items in our financial statements requiring significant estimates and judgments, are as follows:

Research and Development - Research and development expenses consist primarily of compensation and other expenses related to research and development personnel, research collaborations, costs associated with pre-clinical testing and clinical trials of the Company’s product candidates, including the costs of manufacturing drug substance and drug product, regulatory maintenance costs, and facilities expenses, along with the amortization of acquired ANDAs. Research and development costs are expensed as incurred.

Expenses for Clinical Trials - Expenses for clinical trials are incurred from planning through patient enrollment to reporting of the data. We estimate expenses incurred for clinical trials that are in process based on patient enrollment and based on clinical data collection and management. Costs that are associated with patient enrollment are recognized as each patient in the clinical trial completes the enrollment process. Estimated clinical trial costs related to enrollment can vary based on numerous factors, including expected number of patients in trials, the number of patients that do not complete participation in a trial, and when a patient drops out of a trial. Costs that are based on clinical data collection and management are recognized in the reporting period in which services are provided. In the event of early termination of a clinical trial, we accrue an amount based on estimates of the remaining non-cancelable obligations associated with winding down the clinical trial.

Stock-Based Compensation - All stock-based payment transactions are recognized in the consolidated financial statements at their fair values. Compensation expense associated with service and performance condition-based stock options and other equity-based compensation is recorded in accordance with provisions of authoritative guidance. The fair value of awards for which fair values are calculated using the Black-Scholes-Merton option pricing model is generally being amortized on a straight-line basis over the requisite service period and is recognized based on the proportionate amount of the requisite service period that has been rendered during each reporting period. Share-based awards granted to employees with a performance condition are measured based on the probable outcome of that performance condition during the requisite service period. Such an award with a performance condition is expensed when it is probable that a performance condition will be achieved. There was minimal expense recorded for share awards with performance conditions during the nine months ended September 30, 2018 and 2017. Using the straight-line expense attribution method over the requisite service period, which is generally the option vesting term ranging from immediately to one to five years, share-based compensation expense recognized for the nine months ended September 30, 2018 and 2017 totaled approximately $3,517,000 and $516,000, respectively.

The determination of fair value of stock-based payment awards on the date of grant using the Black-Scholes-Merton valuation model is affected by our stock price, as well as the input of other subjective assumptions. These assumptions include, but are not limited to, the expected term of stock options and our expected stock price volatility over the term of the awards. Changes in the assumptions can materially affect the fair value estimates.

Any future changes to our share-based compensation strategy or programs would likely affect the amount of compensation expense recognized.

RESULTS OF OPERATIONS

For the Three and Nine Months Ended September 30, 2018 and 2017.

Revenues and Cost of Product Sales. There were no revenues recorded for the three or nine months ended September 30, 2018 and 2017.

Research and Development Expenses. Our research and development expenses for the three and nine months ended September 30, 2018 totaled approximately $1,806,000 and $5,233,000, respectively. Research and development expenses for the corresponding 2017 periods were $971,000 and $3,748,000, respectively. Included in our research and development expenses for the three-month period ended September 30, 2018 are direct project costs of $398,000 related to our ANDAs acquired in January 2018, $90,000 for ENMD-2076, $242,000 for drugs in-licensed from Spectrum, and $433,000 for preclinical development activities primarily in China. The 2017 R&D expenses for the comparable period are direct project costs of $148,000 for ENMD-2076, $188,000 for drugs in-licensed from Spectrum, and $279,000 for preclinical development activities in China. Research and development expenses totaling $5,233,000 for the nine-month period ended September 30, 2018 included direct project costs of $1,227,000 related to our ANDAs acquired in January 2018, $324,000 related to ENMD-2076, $558,000 for drugs in-licensed from Spectrum, and $1,319,000 for preclinical development activities primarily in China. The 2017 research and development expenses for the comparable period included direct project costs of $697,000 related to ENMD-2076, $1,100,000 for drugs in-licensed from Spectrum, and $837,000 for preclinical development activities in China. The overall increase in research and development costs in the three and nine months ended September 30, 2018, as compared to same periods in 2017, primarily reflects higher costs associated with regulatory costs of the ANDAs in 2018.

At September 30, 2018, and, since acquired, accumulated direct project expenses for our ANDAs acquired in January 2018 totaled $1,227,000; $28,835,000 for ENMD-2076; $5,094,000 for drugs in-licensed from Spectrum; and for preclinical development activities primarily in China, accumulated project expenses totaled $4,675,000. Our research and development expenses also include non-cash stock-based compensation totaling $70,000 and $232,000 for the three and nine months ended September 30, 2018, respectively, and $54,000 and $225,000 for the corresponding 2017 periods, respectively. The balance of our research and development expenditures includes facility costs and other departmental overhead, expenditures related to the non-clinical support of our programs, and non-cash amortization expense of acquired ANDAs.

We expect the majority of our research and development expenses for the rest of 2018 and 2019 to be devoted to advancing our in-licensed products towards market approval in China, the technology transfer activities and regulatory support associated with our ANDA portfolio, and our early-stage candidates in preclinical development. We expect our expenses for the remainder of 2018 and 2019 to increase based on our commercial and clinical development plan. Completion of clinical development may take several years or more, but the length of time generally varies substantially according to the type, complexity, novelty and intended use of a product candidate.

We estimate that clinical trials of the type we generally conduct are typically completed over the following timelines:

Global FDA Trial:

*CLINICAL PHASE*		*ESTIMATED* *COMPLETION* *PERIOD*
Phase 1		1-2 Years
Phase 2		2-3 Years
Phase 3		2-4 Years

Local CFDA Trial:

*CLINICAL PHASE*		*ESTIMATED* *COMPLETION* *PERIOD*
Phase 1		1 Year
Phase 2		2 Years
Phase 3		2-3 Years

The duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during the clinical trial protocol, including, among others, the following:

the number of patients that ultimately participate in the trial;

the duration of patient follow-up that seems appropriate in view of the results;

the number of clinical sites included in the trials; and

the length of time required to enroll suitable patient subjects.

We test our potential product candidates in numerous preclinical studies to identify indications for which they may be product candidates. We may conduct multiple clinical trials to cover a variety of indications for each product candidate. As we obtain results from trials, we may elect to discontinue clinical trials for certain indications in order to focus our resources on more promising indications.

Our proprietary product candidates have also not yet achieved regulatory approval, which is required before we can market them as therapeutic products. In order to proceed to subsequent clinical trial stages and to ultimately achieve regulatory approval, regulatory agencies must conclude that our clinical data establish safety and efficacy. Historically, the results from preclinical testing and early clinical trials have often not been predictive of results obtained in later clinical trials. A number of new drugs and biologics have shown promising results in clinical trials, but subsequently failed to establish sufficient safety and efficacy data to obtain necessary regulatory approvals.

Our business strategy includes being opportunistic with collaborative arrangements with third parties to complete the development and commercialization of our product candidates. In the event that third parties take over the clinical trial process for one of our product candidates, the estimated completion date would largely be under the control of that third party rather than us. We cannot forecast with any degree of certainty which proprietary products or indications, if any, will be subject to future collaborative arrangements, in whole or in part, and how such arrangements would affect our capital requirements.

As a result of the uncertainties discussed above, among others, we are unable to estimate the duration and completion costs of our research and development projects. Our inability to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time-to-time in order to continue with our business strategy. There can be no assurance that we will be able to successfully access external sources of financing in the future. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business.

Research and development expenses consist primarily of compensation and other expenses related to research and development personnel, research collaborations, costs associated with internal and contract preclinical testing and clinical trials of our product candidates, including the costs of manufacturing drug substance and drug product, regulatory maintenance costs, facilities expenses, and amortization expense of acquired ANDAs. Overall research and development expenses increased to $1,806,000 during the three months ended September 30, 2018 from $971,000 for the corresponding period in 2017. Research and development expenses increased to $5,233,000 during the nine-months ended September 30, 2018 from $3,748,000 for the corresponding period in 2017. The fluctuations in research and development expenditures during the three and nine months ended September 30, 2018 were specifically impacted by the following:

Outside Services – We utilize outsourcing to conduct our product development activities. In the three-month period ended September 30, 2018, we expended $176,000 on outside service activities versus $82,000 in the same 2017 period. For the nine-month period ended September 30, 2018 outside services were $622,000 compared to $314,000 for the same 2017 period. The increase in 2018 as compared to 2017 primarily reflects regulatory costs associated with our ANDAs acquired in January 2018.

Clinical Trial Costs – Clinical trial costs, which include clinical site fees, monitoring costs and data management costs, decreased to $24,000 in the three months ended September 30, 2018 from $50,000 in the three-month period ended September 30, 2017. Clinical trial costs for the nine-month period ended September 30, 2018 decreased to $127,000 from $375,000 for the comparable 2017 period. This decrease primarily relates to higher patient costs and clinical trial management costs associated with our Phase 2 clinical trial in advanced fibrolamellar carcinoma (FLC) during the 2017 period compared to the 2018 period as enrollment has completed.

Lab Supplies – Laboratory supplies associated with our pre-clinical activities for the three-month period ended September 30, 2018 increased to $110,000 from $36,000 during the same period in 2017. Laboratory supplies associated with our pre-clinical activities for the nine-month period ended September 30, 2018 increased to $274,000 from $176,000 during the same period in 2017. The variance in both periods is due to the increase in activities at our China research and development lab.

Contract Manufacturing Costs – The costs of manufacturing the material used in clinical trials for our product candidates is reflected in contract manufacturing. These costs include bulk manufacturing, encapsulation and fill and finish services, product release costs and storage fees. Contract manufacturing costs for the three months ended September 30, 2018 increased to $104,000 from ($4,000) during the same period in 2017 due to pre-manufacturing costs associated with the Company’s Cilostazol ANDA incurred during the 2018 period. For the nine-month period ended September 30, 2018, manufacturing costs decreased to $148,000 from $620,000 for the comparable 2017 period. The decrease primarily reflects costs associated with the purchase of EVOMELA^® in China for quality testing purposes to support CASI’s application for import drug registration in the second quarter of 2017.

Personnel Costs – Personnel costs increased to $779,000 in the three-month period ended September 30, 2018 from $591,000 in the corresponding 2017 period. For the nine-month period ended September 30, 2018, personnel costs increased in 2018 to $2,142,000 from $1,583,000 for the corresponding 2017 period. This variance is primarily attributed to increased salary and benefit costs associated with new employees hired in China.

Also reflected in our 2018 research and development expenses for the three-month period ended September 30, 2018 are outsourced consultant costs of ($27,000), facility and related expenses of $196,000, and amortization of acquired ANDAs of $347,000. In the corresponding 2017 period, these expenses totaled $36,000, $125,000, and $0, respectively. For the nine-month period ended September 30, 2018, outsourced consultant costs were $164,000, facility and related expenses were $576,000, and amortization of acquired ANDAs of $945,000. In the corresponding 2017 period, these expenses totaled $177,000, $346,000, and $0, respectively. The variance in outsourced consultant costs reflect the timing of services related to regulatory activities. The increase in facilities and related expenses is due to new leased lab space in China in February 2017 and new leased office space in China in April 2018. The increase in amortization of acquired ANDAs is due to the January 2018 acquisition of ANDAs.

General and Administrative Expenses. General and administrative expenses include compensation and other expenses related to finance, business development and administrative personnel, professional services, investor relations and facilities. General and administrative expenses increased to $6,905,000 in the three-month period ended September 30, 2018 from $626,000 in the corresponding 2017 period. This variance relates to an increase in non-cash stock-based compensation expense totaling $1,524,000, primarily associated with stock option awards issued to the Company’s Executive Chairman; an increase in salary, benefits and recruitment expense totaling approximately $475,000 in China, primarily related to sales and marketing efforts to prepare for the anticipated launch of the Company’s first commercial product in China, as well as other general and administrative functions; approximately $510,000 related to increased professional services fees and investor and public relations activities; and increased facility costs of $121,000 due to new leased office space in China. The increase in general and administrative costs also includes $1,380,000 associated with our Executive Chairman’s services in connection with the September 2018 Financing; and approximately $1,581,000 associated with business development and exploratory acquisition activities during the period, including $1.5 million related to due diligence and related services for certain business development activities incurred by ETP, in which we benefited by having access to the results of those services and did not have to incur such expense on our own. The Company’s Executive Chairman is the founder and managing member of ETP. The Company’s Audit Committee authorized and directed to the Company to reimburse ETP $1.5 million for the expenses incurred in connection with these services.

General and administrative expenses increased to $12,250,000 during the nine months ended September 30, 2018 from $1,961,000 for the corresponding period in 2017. The increase in expenses in the nine-month period in 2018, compared to the same period in 2017 reflects an increase in non-cash stock-based compensation expense totaling $2,994,000, primarily associated with stock option awards issued to the Company’s Executive Chairman; an increase in salary, benefits and recruitment expense totaling $979,000 in China primarily related to sales and marketing efforts to prepare for the anticipated launch of the Company’s first commercial product in China, as well as other general and administrative functions; approximately $901,000 associated with additional professional services fees and investor and public relations activities; and increased facility cost of $229,000 due to new leased office space in China. The increase in general and administrative expenses for the 2018 nine-month period also reflects $1,380,000 associated with our Executive Chairman’s services in connection with the September 2018 Financing and increased costs of approximately $2,546,000 associated with business development and exploratory acquisition activities, including the $1.5 million of expenses associated with ETP as described above.

Acquired In-process Research and Development. In January 2018, we acquired a portfolio of 29 ANDAs, including 25 FDA-approved ANDAs and four pipeline ANDAs that are pending FDA approval, limited quantities of API, and certain manufacturing and other information related to the products (collectively, the ANDAs, API and other information are referred to as the “Acquired Assets”). The total purchase price for the Acquired Assets was $18.0 million in cash. We accounted for the purchase of the Acquired Assets as an asset acquisition (consisting of a concentrated group of similar identifiable assets, including ANDAs and API). The total purchase price, along with approximately $1.2 million of transaction expenses, was allocated to the Acquired Assets based on their relative fair values. Of the total value allocated to the ANDAs, approximately $553,000 was immediately expensed as acquired in-process research and development since the underlying ANDAs have not been approved by the FDA, and of the total value allocated to the API, approximately $134,000 was immediately expensed as acquired in-process research and development since the Company does not intend to use all the API.

Interest (income) expense, net. Interest (income) expense, net for the three months ended September 30, 2018 and 2017 was $(10,652) and $546, respectively. This includes interest on our note payable of $1,875 for both periods; non-cash interest of $177 and $1,869, respectively, representing the amortization of the debt discount; offset by interest income of $12,704 and $3,198, respectively. Interest (income) expense, net for the nine months ended September 30, 2018 and 2017 was $(30,453) and $476, respectively. This includes interest on our note payable of $5,625 for both periods; non-cash interest of $531 and $5,607, respectively, representing the amortization of the debt discount; offset by interest income of $36,609 and $10,756, respectively.

Other expense. Other expense for the three and nine months ended September 30, 2018 was $55,941 and $67,266, respectively, representing unrealized losses on the Company’s equity investment securities.

Change in fair value of contingent rights. The Contingent Rights issued to Spectrum in connection with the license arrangements are considered derivative liabilities and were recorded initially at their estimated fair value and are marked to market each reporting period until settlement. The Contingent Rights were fully settled during 2017, so there was no change in the fair value of the Contingent Right for the three and nine months ended September 30, 2018. The change in fair value of the Contingent Rights for the three and nine months ended September 30, 2017 was $16,110 and $12,665, respectively.

LIQUIDITY AND CAPITAL RESOURCES

To date, we have been engaged primarily in research and development activities. As a result, we have incurred and expect to continue to incur operating losses in 2018 and the foreseeable future before we commercialize any products and penetrate significant markets such as China. Based on our current plans, we expect our current available cash and cash equivalents to meet our cash requirements for at least through November 14, 2019.

We will require significant additional funding to fund operations until such time, if ever, we become profitable. We intend to augment our cash balances by pursuing other forms of capital infusion, including strategic alliances or collaborative development opportunities with organizations that have capabilities and/or products that are complementary to our capabilities and products in order to continue the development of our potential product candidates that we intend to pursue to commercialization. If we seek strategic alliances, licenses, or other alternative arrangements, such as arrangements with collaborative partners or others, to raise further financing, we may need to relinquish rights to certain of our existing product candidates, or products we would otherwise seek to develop or commercialize on our own, or to license the rights to our product candidates on terms that are not favorable to us.

We will continue to seek to raise additional capital to fund our commercialization efforts, expansion of our operations, research and development, and for the acquisition of new product candidates, if any. We intend to explore one or more of the following alternatives to raise additional capital:

selling additional equity securities;

out-licensing product candidates to one or more corporate partners;

completing an outright sale of non-priority assets; and/or

engaging in one or more strategic transactions.

We also will continue to manage our cash resources prudently and cost-effectively.

There can be no assurance that adequate additional financing under such arrangements will be available to us on terms that we deem acceptable, if at all. If additional funds are raised by issuing equity securities, dilution to existing stockholders may result, or the equity securities may have rights, preferences, or privileges senior to those of the holders of our common stock. If we fail to obtain additional capital when needed, we may be required to delay or scale back our commercialization efforts, our advancement of the Spectrum products, and the ANDA products, or plans for other product candidates, if any.

At September 30, 2018, we had cash and cash equivalents of approximately $98.9 million, with working capital of approximately $94.5 million. As of September 30, 2018, approximately $15.2 million of the Company’s cash balance was held by the Company’s wholly-owned subsidiary in China.

As a result of the Company’s acquisition of a portfolio of ANDAs, we believe that this transaction provides significant and permanent changes to our operations in China, and that may allow our subsidiary in China to generate operating revenues from the China marketplace in the future and potentially to sustain its own operations without the necessity of parent support. Accordingly, effective January 1, 2018, the functional currency of the Company’s subsidiary based in China has been changed to the local currency of the China RMB. The change in functional currency did not have a material impact on the consolidated financial statements.

FINANCING ACTIVITIES

“Shelf” Registration Statement

On December 13, 2017, we filed a Form S-3 registration statement with the SEC utilizing a “shelf” registration process. On December 22, 2017, the Form S-3 registration statement was declared effective by the SEC. Pursuant to this shelf registration statement, we may sell debt or equity securities in one or more offerings up to a total public offering price of $100 million. We believe that this shelf registration statement currently provides us additional flexibility with regard to potential financings that we may undertake when market conditions permit or our financial condition may require.

Securities Purchase Agreements

As discussed above, in September 2018, the Company entered into securities purchase agreements the (“Securities Purchase Agreements”) with certain institutional investors, accredited investors and current stockholders, pursuant to which the Company agreed to sell 9,048,504 shares of its common stock with accompanying warrants to purchase 2,714,548 shares of its common stock in a $48.5 million private placement. The purchase price for each share of common stock and warrant was $5.36. The warrants will become exercisable on March 23, 2019 at a $7.19 per share exercise price and will expire on September 24, 2021. On September 24, 2018, the Company completed its first closing and issued 6,809,699 shares of its common stock with accompanying warrants to purchase 2,042,907 shares of its common stock and received $36.5 million in gross proceeds. The fair value of the warrants issued is $6,087,863, or $2.98 per warrant, calculated using the Black-Scholes-Merton valuation model with a contractual life of 3 years, an assumed volatility of 88.39%, and a risk-free interest rate of 2.89%. On October 10, 2018, the Company completed its second closing for an additional $1 million in gross proceeds, which was received in September 2018. The Company expects to close on the remaining $11 million of the September 2018 Financing. The Securities Purchase Agreements and warrants each include additional customary representations, warranties and covenants. The Company also agreed to file a resale registration within 120 days following the closing covering the shares of common stock issued and the shares of common stock underlying the warrants.

Additionally, in March 2018, the Company entered into securities purchase agreements with certain institutional investors, accredited investors and current stockholders, pursuant to which the Company issued 15,432,091 shares of its common stock with accompanying warrants to purchase 6,172,832 shares of its common stock and received $50 million in gross proceeds in a private placement. The purchase price for each share of common stock and warrant was $3.24. The warrants became exercisable on September 17, 2018 at a $3.69 per share exercise price, and will expire on March 21, 2023. The fair value of the warrants issued is $15,062,000, or $2.44 per warrant, calculated using the Black-Scholes-Merton valuation model with a contractual life of 5 years, an assumed volatility of 75.4%, and a risk-free interest rate of 2.69%. The securities purchase agreements and warrants each include additional customary representations, warranties and covenants. The Company has filed a resale registration covering the shares of common stock issued and the shares of common stock underlying the warrants on Form S-3 (File No. 333-226206) which became effective on August 8, 2018.

Common Stock Sales Agreement

INFLATION AND INTEREST RATE CHANGES

Management does not believe that our working capital needs are sensitive to inflation and changes in interest rates.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The primary objective of our investment activities is to preserve our capital until it is required to fund operations while at the same time maximizing the income we receive from our investments without incurring investment market volatility risk. Our investment income is sensitive to the general level of U.S. interest rates. In this regard, changes in the U.S. interest rates affect the interest earned on our cash and cash equivalents. Due to the short-term nature of our cash and cash equivalent holdings, a 10% movement in market interest rates would not materially impact the total fair market value of our portfolio as of September 30, 2018.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Based on an evaluation under the supervision and with the participation of the Company’s management, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) were effective as of September 30, 2018 to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

We believe that a controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company’s internal control over financial reporting that occurred during the quarter ended September 30, 2018 that have materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

We are subject in the normal course of business to various legal proceedings in which claims for monetary or other damages may be asserted. Management does not believe such legal proceedings, unless otherwise disclosed herein, are material.

ITEM 1A.

RISK FACTORS

For information regarding factors that could affect the Company’s results of operations, financial condition and liquidity, see the risk factors discussion set forth in Item 1A of CASI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and the information under “Special Note Regarding Forward-Looking Statements” included in this report. There have been no material changes to our risk factors from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4.

REMOVED AND RESERVED

ITEM 5.

OTHER INFORMATION

Not applicable.

ITEM 6.

EXHIBITS

4.1		Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed with the Securities and Exchange Commission on September 14, 2018)
10.1		Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the Securities and Exchange Commission on September 14, 2018)
10.2		Employment Agreement, effective as of September 28, 2018, between the Company and George Chi (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K/A filed with the Securities and Exchange Commission on October 24, 2018)
31.1		Rule 13a-14(a) Certification of Chief Executive Officer*
31.2		Rule 13a-14(a) Certification of Chief Financial Officer*
32.1		Section 1350 Certification of Chief Executive Officer*
32.2		Section 1350 Certification of Chief Financial Officer*
101		The following financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, formatted in eXtensible Business Reporting Language (XBRL): (i) Unaudited Condensed Consolidated Balance Sheets at September 30, 2018 and December 31, 2017, (ii) Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2018 and 2017, (iii) Unaudited Condensed Consolidated Statement of Stockholders’ Equity for the Nine Months Ended September 30, 2018, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2018 and 2017, and (v) Notes to Unaudited Condensed Consolidated Financial Statements.*

* Filed Herewith

EXHIBIT INDEX

4.1		Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed with the Securities and Exchange Commission on September 14, 2018)
10.1		Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the Securities and Exchange Commission on September 14, 2018)
10.2		Employment Agreement, effective as of September 28, 2018, between the Company and George Chi (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K/A filed with the Securities and Exchange Commission on October 24, 2018)
31.1		Rule 13a-14(a) Certification of Chief Executive Officer*
31.2		Rule 13a-14(a) Certification of Chief Financial Officer*
32.1		Section 1350 Certification of Chief Executive Officer*
32.2		Section 1350 Certification of Chief Financial Officer*
101		The following financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, formatted in eXtensible Business Reporting Language (XBRL): (i) Unaudited Condensed Consolidated Balance Sheets at September 30, 2018 and December 31, 2017, (ii) Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2018 and 2017, (iii) Unaudited Condensed Consolidated Statement of Stockholders’ Equity for the Nine Months Ended September 30, 2018, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2018 and 2017, and (v) Notes to Unaudited Condensed Consolidated Financial Statements.*

* Filed Herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CASI PHARMACEUTICALS, INC.
	(Registrant)

Date: November 14, 2018	/s/ Ken K. Ren
	Ken K. Ren
	Chief Executive Officer

Date: November 14, 2018	/s/George Chi
	George Chi
	Chief Financial Officer

EX-31.1 2 tv506426_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Ken K. Ren, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CASI Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of condensed consolidated financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2018

/s/ Ken K. Ren
Ken K. Ren
Chief Executive Officer

EX-31.2 3 tv506426_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, George Chi, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CASI Pharmaceuticals, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2018

/s/ George Chi
George Chi
Chief Financial Officer

EX-32.1 4 tv506426_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION BY CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CASI Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ken K. Ren, as Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

Date: November 14, 2018	/s/ Ken K. Ren
	Ken K. Ren Chief Executive Officer

EX-32.2 5 tv506426_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION BY CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CASI Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, George Chi, as Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

Date: November 14, 2018	/s/ George Chi
	George Chi
	Chief Financial Officer

EX-101.INS 6 casi-20180930.xml XBRL INSTANCE DOCUMENT 0000895051 2018-01-01 2018-09-30 0000895051 2018-09-30 0000895051 2017-12-31 0000895051 2017-01-01 2017-09-30 0000895051 2018-01-01 2018-01-31 0000895051 2018-07-01 2018-09-30 0000895051 2017-07-01 2017-09-30 0000895051 2018-11-07 0000895051 2018-09-01 2018-09-24 0000895051 2018-03-01 2018-03-31 0000895051 2016-12-31 0000895051 2017-09-30 0000895051 us-gaap:WarrantMember 2018-01-01 2018-09-30 0000895051 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0000895051 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0000895051 casi:AbbreviatedNewDrugApplicationsMember 2018-01-01 2018-09-30 0000895051 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0000895051 us-gaap:AccountingStandardsUpdate201701Member 2018-01-01 2018-09-30 0000895051 casi:AbbreviatedNewDrugApplicationsMember 2018-01-01 2018-09-30 0000895051 casi:ActivePharmaceuticalIngredientMember 2018-01-01 2018-09-30 0000895051 casi:SpectrumPharmaceuticalsMember 2018-01-01 2018-09-30 0000895051 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0000895051 us-gaap:PreferredStockMember 2018-01-01 2018-09-30 0000895051 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0000895051 us-gaap:TreasuryStockMember 2018-01-01 2018-09-30 0000895051 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0000895051 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0000895051 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0000895051 casi:CommonStockToBeIssuedMember 2018-01-01 2018-09-30 0000895051 casi:LongTermIncentivePlan2011Member srt:MinimumMember 2018-01-01 2018-09-30 0000895051 us-gaap:InvestorMember 2018-01-01 2018-09-30 0000895051 casi:LongTermIncentivePlan2011Member srt:MaximumMember 2018-01-01 2018-09-30 0000895051 srt:MinimumMember 2018-01-01 2018-09-30 0000895051 srt:MaximumMember 2018-01-01 2018-09-30 0000895051 us-gaap:PrivatePlacementMember 2018-01-01 2018-09-30 0000895051 casi:EmergingTechnologyPartnersLLCMember 2018-01-01 2018-09-30 0000895051 us-gaap:BoardOfDirectorsChairmanMember 2018-01-01 2018-09-30 0000895051 us-gaap:ExecutiveOfficerMember 2018-01-01 2018-09-30 0000895051 casi:SecondClosingMember 2018-01-01 2018-09-30 0000895051 casi:SecuritiesPurchaseAgreementsMember 2018-01-01 2018-09-30 0000895051 us-gaap:FairValueInputsLevel1Member 2018-09-30 0000895051 casi:AbbreviatedNewDrugApplicationsMember 2018-09-30 0000895051 us-gaap:PublicUtilitiesInventoryRawMaterialsMember 2018-09-30 0000895051 casi:SpectrumPharmaceuticalsMember 2018-09-30 0000895051 casi:LongTermIncentivePlan2011Member 2018-09-30 0000895051 casi:CasiChinaMember 2018-09-30 0000895051 casi:LongTermIncentivePlan2011Member srt:MinimumMember 2018-09-30 0000895051 casi:LongTermIncentivePlan2011Member srt:MaximumMember 2018-09-30 0000895051 us-gaap:BoardOfDirectorsChairmanMember 2018-09-30 0000895051 casi:EmergingTechnologyPartnersLLCMember 2018-09-30 0000895051 casi:LeaseInChinaMember 2017-12-31 0000895051 casi:LeaseInRockvilleMember 2017-12-31 0000895051 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0000895051 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-09-30 0000895051 casi:SpectrumMember 2017-01-01 2017-09-30 0000895051 casi:EmergingTechnologyPartnersLLCMember 2018-07-01 2018-09-30 0000895051 casi:SecuritiesPurchaseAgreementsMember 2018-03-01 2018-03-31 0000895051 casi:SalesAgreementMember 2018-03-01 2018-03-31 0000895051 casi:SecuritiesPurchaseAgreementsMember us-gaap:MeasurementInputExpectedTermMember 2018-03-01 2018-03-31 0000895051 casi:SecuritiesPurchaseAgreementsMember us-gaap:MeasurementInputPriceVolatilityMember 2018-03-01 2018-03-31 0000895051 casi:SecuritiesPurchaseAgreementsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-03-01 2018-03-31 0000895051 casi:ExecutiveChairmanMember 2018-03-13 0000895051 casi:ExecutiveChairmanMember casi:PerformanceBasedOptionMember 2018-03-13 0000895051 casi:SecuritiesPurchaseAgreementsMember 2018-09-01 2018-09-24 0000895051 us-gaap:InvestorMember 2018-09-01 2018-09-24 0000895051 casi:SecuritiesPurchaseAgreementsMember us-gaap:MeasurementInputExpectedTermMember 2018-09-01 2018-09-24 0000895051 us-gaap:MeasurementInputPriceVolatilityMember casi:SecuritiesPurchaseAgreementsMember 2018-09-01 2018-09-24 0000895051 us-gaap:MeasurementInputRiskFreeInterestRateMember casi:SecuritiesPurchaseAgreementsMember 2018-09-01 2018-09-24 0000895051 us-gaap:PrivatePlacementMember 2018-09-01 2018-09-24 0000895051 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2018-09-01 2018-09-24 0000895051 us-gaap:WarrantMember us-gaap:InvestorMember 2018-09-24 0000895051 us-gaap:InvestorMember 2018-09-24 0000895051 us-gaap:SubsequentEventMember 2018-10-01 2018-10-31 0000895051 casi:HcWainwrightCoLlcMember srt:MaximumMember 2018-02-23 0000895051 us-gaap:InvestorMember 2018-03-31 0000895051 us-gaap:InvestorMember us-gaap:SubsequentEventMember 2018-09-01 2018-10-31 0000895051 us-gaap:SubsequentEventMember 2018-11-01 0000895051 us-gaap:SubsequentEventMember 2018-01-01 2018-10-31 0000895051 us-gaap:WarrantMember 2017-12-31 0000895051 us-gaap:EmployeeStockOptionMember 2017-12-31 0000895051 us-gaap:WarrantMember 2018-09-30 0000895051 us-gaap:PreferredStockMember 2017-12-31 0000895051 us-gaap:CommonStockMember 2017-12-31 0000895051 us-gaap:TreasuryStockMember 2017-12-31 0000895051 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000895051 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000895051 us-gaap:RetainedEarningsMember 2017-12-31 0000895051 casi:CommonStockToBeIssuedMember 2017-12-31 0000895051 us-gaap:EmployeeStockOptionMember 2018-09-30 0000895051 us-gaap:PreferredStockMember 2018-09-30 0000895051 us-gaap:CommonStockMember 2018-09-30 0000895051 us-gaap:TreasuryStockMember 2018-09-30 0000895051 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000895051 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000895051 us-gaap:RetainedEarningsMember 2018-09-30 0000895051 casi:CommonStockToBeIssuedMember 2018-09-30 10-Q false 2018-09-30 2018 Q3 CASI Pharmaceuticals, Inc. 0000895051 --12-31 Non-accelerated Filer CASI 93587515 false true

98867087

43489935

1165046

1343667

322493

101375800

43812428

1594189

1046514

228431

242023

17110422

120308842

45100965

1740611

2087770

2880000

2228366

800975

745961

6920871

5062097

1498754

6987438

6560851

934804

699015

590322314

498577372

8034244

-1224748

-469676722

-452702029

113321404

120308842

45100965

1 9048504 37500000

15432091

6172832

15200000

18608000 564000 19172000

553000

134000

P13Y

18000000

1200000

18054985

-944563

347212

1388845

11207830

1200000

430000

531

5607

0.005

136000

1500000

2.98 5.36

143248

475000 24500000

18384932

13425608

1806222

970989

5232925

3747683

6904800

625878

12250269

1961463

8711022

1596867

18170192

5709146

10652

-546

30453

-476

16110

-8756311

-1613523

-0.10

-0.03

-0.22

-0.10

86953611

60196574

81457085

60196574

-685106

-1224748

-9441417

-1613523

-19431753

-5722287

6878610

232230

225342

3285263

290895

3517493

516237

0.04 0.01

0.7879

0.7892

0.0280

0.0197

0.00000

4.51

0.73

11585315

156283

7286000

279970

50130

18384932

8753696

1.42

1.65

4.02

1.50

3.28

2.44

1.59

6264016

8215739

1054147

13425608 11382701 2.23 4.56 1.98 0 3.68 3.04

66567

1000000 0

55941

67266

699015

-8034244

498577372

-452702029

38540114

69822080

1232312

223850

86766366

86990216

22385038

1397

256551

257948

139683

0 10542 0 2077493 0 0 2088035 0 0 1054147

755767

3517493

-1224748

-18207005

934804

-8034244

590322314

-1224748

-469676722

1000000

93400948

-117194

1000000 1000000

-18207005

-5722287

249738

69420

944563

686998

-67266

531

5607

12665

610795

119686

-326535

139339

651634

146149

51694

-12874536

-5047011

861667

405849

19171956

-20033024

-405849

755767

86990216 0

89463238

-1178526

55377152

-5452860

27092928

21640068

0.8839 0.0289 P3Y

18384932

0.86

1000000

4000000

8.23

257948

P2Y P5Y

2088035

3200000

477000

9200000

139300

557200

139300

1499285

1.00

5000000

1.00

5000000

1700000000

186567

93480493

69901625

79545

0 0 0 0 0 0

-5427

599

1000000 0

117194

50000000 <table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px; vertical-align: top; width: 0.3pt; font-size: 10pt; line-height: 10pt;"></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: top; width: 36pt; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: top; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Acquisition of Abbreviated New Drug Applications</div></div></div></td></tr></table><div style="text-align:left;"><div style="clear:both;"></div><div style="clear:both;"></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On January 26, 2018, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Sandoz, Inc. (“Sandoz”). Pursuant to the Asset Purchase Agreement, the Company acquired a portfolio of 29 abbreviated new drug applications (“ANDAs”), including 25 ANDAs approved by the U.S. Food and Drug Administration (“FDA”) and four pipeline ANDAs that are pending FDA approval, limited quantities of certain active pharmaceutical ingredient (“API”), and certain manufacturing and other information related to the products (collectively, the ANDAs, API and other information are referred to as the “Acquired Assets”). To facilitate the sale and transition, the parties also entered into several limited term ancillary arrangements.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Acquired Assets enhance the Company’s strategic focus to build a robust pipeline and commercialize quality drug candidates in China. The Company intends to select and commercialize certain products from the portfolio that have unique market and cost-effective manufacturing opportunities in China (and potentially in the U.S.).</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The total purchase price for the Acquired Assets was $18.0 million in cash. The Company accounted for the purchase of the Acquired Assets as an asset acquisition (consisting of a concentrated group of similar identifiable assets, including ANDAs and API) following the guidance contained in Accounting Standards Update (“ASU”) 2017-01. The total purchase price, along with approximately $1.2 million of transaction expenses, was allocated to the Acquired Assets based on their relative fair values, as follows:</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 40%;"><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 80%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ANDAs</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 17%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">18,608,000</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">API</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">564,000</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total value</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">19,172,000</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Of the total value allocated to the ANDAs, approximately $553,000 was immediately expensed as acquired in-process research and development since the underlying ANDAs have not been approved by the FDA, and of the total value allocated to the API, approximately $134,000 was immediately expensed as acquired in-process research and development since the Company does not intend to use all of the API. The allocated cost of the capitalized ANDAs will be amortized over their estimated useful lives of 13 years. The capitalized API will be expensed in the period it is used or if its value is otherwise impaired.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The fair values of certain acquired ANDAs were estimated using the discounted cash flow method (an income approach), which involves the use of Level 3 inputs such as estimates for projected sales, expenses, and cash flows, estimates of total addressable markets and market penetration rates, future sales growth and inflation rates, expected income and value-added tax rates, and a required rate of return adjusted for both industry and Company-specific risks, among other inputs. The fair values of the remaining ANDAs were estimated using a multiple of values method (an income approach), which involved using Level 3 inputs such as estimated addressable markets and market penetration rates. The fair value of the API was estimated using Level 2 inputs, such as quoted market prices for similar API from various suppliers or other sources. The ANDAs will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable; no such triggering events were identified during the period from the date of acquisition to September 30, 2018.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"></div><div style="text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 40%;"><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 80%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ANDAs</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 17%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">18,608,000</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">API</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">564,000</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total value</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">19,172,000</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div></div><div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;">Net finite-lived intangible assets at September 30, 2018 consists of the following:</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 90%;"><tr><td style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Asset</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross Value</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated Amortization</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated useful lives</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 33%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ANDAs</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 20%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">18,054,985</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 20%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(944,563</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 20%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">13 years</div></div></td></tr></table><div style="clear:both;"></div></div>

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.69in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected future amortization expense is as follows for the years ending December 31:</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; margin-left: 0.5in; width: 65%;"><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 82%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2018 (remaining three months)</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 15%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">347,212</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,388,845</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,388,845</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,388,845</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,388,845</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2023 and thereafter</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">11,207,830</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear:both;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

P13Y

<table cellpadding="0" cellspacing="0" style="font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align: top; text-align: justify;"><td style="width: 0px; padding: 0px;"></td><td style="width: 0.5in; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">10.</div></td><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Stockholders’ Equity</div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Securities Purchase Agreements</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As described in Note 1, in September 2018, the Company entered into securities purchase agreements the (“Securities Purchase Agreements”) with certain institutional investors, accredited investors and current stockholders, pursuant to which the Company agreed to sell 9,048,504 shares of its common stock with accompanying warrants to purchase 2,714,548 shares of its common stock in a $48.5 million private placement. The purchase price for each share of common stock and warrant was $5.36. The warrants will become exercisable on March 23, 2019 at a $7.19 per share exercise price and will expire on September 24, 2021. On September 24, 2018, the Company completed its initial closing, the September 2018 Closing, and issued 6,809,699 shares of its common stock with accompanying warrants to purchase 2,042,907 shares of its common stock and received $36.5 million in gross proceeds. The fair value of the warrants issued is $6,087,863, or $2.98 per warrant, calculated using the Black-Scholes-Merton valuation model with a contractual life of 3 years, an assumed volatility of 88.39%, and a risk-free interest rate of 2.89%. On October 10, 2018, the Company completed its second closing, the October 2018 Closing, on an additional $1 million in gross proceeds, which was received in September 2018 and reflected as “common stock to be issued” on the accompanying condensed consolidated balance sheet as of September 30, 2018. The Company expects to close on the remaining $11 million. The Securities Purchase Agreements and warrants each include additional customary representations, warranties and covenants. The Company also agreed to file a resale registration within 120 days following the closing covering the shares of common stock issued and the shares of common stock underlying the warrants.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s Executive Chairman, and the Company’s Chief Executive Officer played a key role in identifying and securing potential investors for the September 2018 Financing. As a result, the Company did not have to pay a commission to, or incur additional expenses for, a placement agent. In exchange for their services, which were deemed to be outside the scope of their responsibilities as officers and directors of the Company, the Company’s Audit Committee approved payments of $1,460,000 and $480,000 to the Executive Chairman and the Chief Executive Officer, respectively. As of September 30, 2018, $1,380,000 and $120,000 of these payments, respectively, have been earned and are included as general and administrative expenses in the accompanying condensed consolidated statement of operations for the three and nine month periods ended September 30, 2018. The amount payable to the Executive Chairman totaling $1,380,000 is included in “payable to related parties” in the accompanying condensed consolidated balance sheet as of September 30, 2018 and was paid in October 2018.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As described in Note 1, in March 2018, the Company entered into securities purchase agreements with certain institutional investors, accredited investors and current stockholders, pursuant to which the Company issued 15,432,091 shares of its common stock with accompanying warrants to purchase 6,172,832 shares of its common stock and received $50 million in gross proceeds in a private placement. The purchase price for each share of common stock and warrant was $3.24. The warrants became exercisable on September 17, 2018 at a $3.69 per share exercise price and will expire on March 21, 2023. The fair value of the warrants issued is $15,062,000, or $2.44 per warrant, calculated using the Black-Scholes-Merton valuation model with a contractual life of 5 years, an assumed volatility of 75.4%, and a risk-free interest rate of 2.69%. The securities purchase agreements and warrants each include additional customary representations, warranties and covenants. The Company filed a resale registration covering the shares of common stock issued and the shares of common stock underlying the warrants on Form S-3 (File No. 333-226206) which became effective on August 8, 2018.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock Sales Agreement</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On February 23, 2018, the Company entered into a Common Stock Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“HCW”). Pursuant to the terms of the Sales Agreement, the Company may sell from time-to-time, at its option, shares of the Company’s common stock through HCW, as sales agent, with an aggregate sales price of up to $25 million (the “Shares”).</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Any sales of Shares pursuant to the Sales Agreement will be made under the Company’s effective “shelf” registration statement (the “Registration Statement”) on Form S-3 (File No. 333-222046) which became effective on December 22, 2017 and the related prospectus supplement and the accompanying prospectus, as filed with the Securities and Exchange Commission (the “SEC”) on February 23, 2018.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In March 2018, the Company issued 143,248 Shares under the Sales Agreement resulting in net proceeds to the Company of approximately $475,000. As of September 30, 2018, approximately $24.5 million remained available under the Sales Agreement.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

6809699

2042907 6087863

7.19

1000000 11000000 1460000 480000

1380000

120000

1380000

36500000 15062000 2.44

50000000

3.24

3.69

0.754 0.0269 P5Y 2714548 48500000

90600

<div style="text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px; vertical-align: top; width: 0.3pt; font-size: 10pt; line-height: 10pt;"></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: top; width: 36pt; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: top; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock-Based Compensation and Warrants</div></div></div></td></tr></table><div style="clear:both;"></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company has adopted incentive and nonqualified stock option plans for executive, scientific and administrative personnel of the Company as well as outside directors and consultants. In June 2018, the Company’s stockholders approved an amendment to the 2011 Long-Term Incentive Plan, increasing the number of shares of common stock reserved for issuance from 14,230,000 to 20,230,000 to be available for grants and awards. As of September 30, 2018, there are 18,384,932 shares issuable under options previously granted and currently outstanding, with exercise prices ranging from $0.86 to $8.23. Options granted under the plans generally vest over periods varying from immediately to one to five years, are not transferable and generally expire ten years from the date of grant. As of September 30, 2018, 6,878,610 shares remained available for grant under the Company’s 2011 Long-Term Incentive Plan. On March 13, 2018, upon the recommendation of the Compensation Committee of the Board of Directors (the “Board”), the Board approved a grant of stock options to the Company’s Executive Chairman exercisable for 1 million shares of common stock that will vest and become exercisable on the first anniversary date of the grant. In addition, the Board approved the grant of a performance-based option covering 4 million shares of common stock that will vest if, within 18 months of the date of grant, specific operational and strategic milestones are achieved. Both grants were approved by the Company’s stockholders at the 2018 Annual Meeting of Stockholders.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company records compensation expense associated with stock options and other equity-based compensation in accordance with provisions of authoritative guidance. Compensation costs are recognized over the requisite service period, which is generally the option vesting term of up to five years. Awards with performance conditions are expensed when it is probable that the performance condition will be achieved. There was minimal expense recorded for share awards with performance conditions during the nine months ended September 30, 2018 and 2017.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s net loss for the nine months ended September 30, 2018 and 2017 includes $3,517,493 and $516,237, respectively, of non-cash compensation expense related to the Company’s share-based compensation awards. The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense, as follows:</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%;"><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Month Period ended September 30,</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 74%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">232,230</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">225,342</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3,285,263</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">290,895</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3,517,493</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">516,237</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Net share-based compensation expense, per common share:</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.04</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.01</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear:both;"></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company uses the Black-Scholes-Merton valuation model to estimate the fair value of service based and performance-based stock options granted to employees. Option valuation models, including Black-Scholes-Merton, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award. Following are the weighted-average assumptions used in valuing the stock options granted to employees during the nine-month periods ended September 30, 2018 and 2017:</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%;"><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Month Period ended September 30,</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 74%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">78.79</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">78.92</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Risk free interest rate</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.80</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1.97</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected term of option</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5.77 years</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6.34 years</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.00</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.00</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr></table><div style="clear:both;"></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The weighted average fair value of stock options granted during the nine-month periods ended September 30, 2018 and 2017 were $4.51 and $0.73, respectively.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A summary of the Company's stock option plans and of changes in options outstanding under the plans during the nine-month period ended September 30, 2018 is as follows:</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 90%;"><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of Options</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average </div></div><br/><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise Price</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 74%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 1, 2018</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">11,585,315</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1.42</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(156,283</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1.65</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7,286,000</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">4.02</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expired</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(279,970</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1.50</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(50,130</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3.28</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2018</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">18,384,932</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.44</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2018</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8,753,696</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1.59</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear:both;"></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash received from option exercises under all share-based payment arrangements for the nine months ended September 30, 2018 was $257,948. There were no option exercises during the nine months ended September 30, 2017.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Warrants </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Warrants issued generally expire after 2-5 years from the date of issuance. Stock warrant activity is as follows:</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 90%;"><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of Warrants</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average </div></div><br/><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise Price</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 74%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 1, 2018</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6,264,016</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.23</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Issued</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8,215,739</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">4.56</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(1,054,147</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1.98</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expired</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2018</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">13,425,608</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3.68</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2018</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">11,382,701</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3.04</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear:both;"></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash received from warrants exercised during the nine months ended September 30, 2018 was $2,088,035. There were no warrants exercised during the nine months ended September 30, 2017.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s net loss for the nine months ended September 30, 2018 and 2017 includes $3,517,493 and $516,237, respectively, of non-cash compensation expense related to the Company’s share-based compensation awards. The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense, as follows:</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%;"><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Month Period ended September 30,</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 74%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">232,230</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">225,342</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3,285,263</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">290,895</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3,517,493</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">516,237</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Net share-based compensation expense, per common share:</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.04</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.01</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear:both;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A summary of the Company's stock option plans and of changes in options outstanding under the plans during the nine-month period ended September 30, 2018 is as follows:</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 90%;"><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of Options</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average </div></div><br/><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise Price</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 74%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 1, 2018</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">11,585,315</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1.42</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(156,283</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1.65</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7,286,000</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">4.02</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expired</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(279,970</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1.50</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(50,130</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3.28</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2018</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">18,384,932</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.44</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2018</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8,753,696</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1.59</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear:both;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Warrants issued generally expire after 2-5 years from the date of issuance. Stock warrant activity is as follows:</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 90%;"><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of Warrants</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average </div></div><br/><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise Price</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 74%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 1, 2018</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6,264,016</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.23</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Issued</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8,215,739</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">4.56</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(1,054,147</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1.98</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt 9pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expired</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2018</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">13,425,608</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3.68</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2018</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">11,382,701</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3.04</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear:both;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;">Following are the weighted-average assumptions used in valuing the stock options granted to employees during the nine-month periods ended September 30, 2018 and 2017:</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%;"><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Month Period ended September 30,</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 74%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">78.79</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">78.92</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Risk free interest rate</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.80</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1.97</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected term of option</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5.77 years</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6.34 years</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.00</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.00</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr></table><div style="clear:both;"></div></div>

P5Y9M7D

P6Y4M2D

14230000

20230000

48500000

0.01

6068

<table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px; vertical-align: top; width: 0.3pt; font-size: 10pt; line-height: 10pt;"></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: top; width: 36pt; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: top; font-size: 10pt; line-height: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subsequent Event</div></div></div></td></tr></table><div style="clear:both;"></div><div style="text-align:left;"><div style="clear:both;"></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In October 2018, the Company entered into an agreement with Laurus Labs Limited (</div>“Laurus”<div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">), a company organized under the Laws of India, pursuant to which the Company will acquire from Laurus one U.S. FDA-approved abbreviated new drug application for tenofovir disoproxil fumarate (TDF ANDA), which is indicated for the treatment of hepatitis B virus. The aggregate purchase price for the TDF ANDA was $3 million, with an upfront payment of $700,000, paid in October 2018, and $2.3 million to be paid upon completion of certain milestones.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

25000000

1500000

418000

383100

418000

8400

50500

138600

142700

85700

3000000 700000 2300000

1500000

3000000

iso4217:USD xbrli:pure xbrli:shares utr:sqft iso4217:USD xbrli:shares

EX-101.SCH 7 casi-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Consolidated Statement of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1007 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Acquisition of Abbreviated New Drug Applications link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Intangible Assets link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Foreign Currency Translation link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Investments link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Research and Development link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - License Arrangements link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Note Payable link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Net Loss Per Share link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Stock-Based Compensation and Warrants link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - New Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Commitments link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Subsequent Event link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Acquisition of Abbreviated New Drug Applications (Tables) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Stock-Based Compensation and Warrants (Tables) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Basis of Presentation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Acquisition of Abbreviated New Drug Applications (Details) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Acquisition of Abbreviated New Drug Applications (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Intangible Assets (Details) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Intangible Assets (Details 1) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Intangible Assets (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Investments (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Inventories (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Note Payable (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Net Loss Per Share (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Stock-Based Compensation and Warrants (Details) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Stock-Based Compensation and Warrants (Details 1) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Stock-Based Compensation and Warrants (Details 2) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Stock-Based Compensation and Warrants (Details 3) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Stock-Based Compensation and Warrants (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Related Party Transactions (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Commitments (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1046 - Disclosure - Subsequent Event (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 casi-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 casi-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 casi-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Class of Stock [Domain] Document Information [Line Items] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Entity Emerging Growth Company Entity Small Business Statement of Financial Position [Abstract] Statement [Table] Legal Entity [Axis] Entity [Domain] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Short-term Investments Investments, at fair value Prepaid Expense and Other Assets, Current Prepaid expenses and other Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Other Assets, Noncurrent Other assets Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accounts Payable, Related Parties, Current Payable to related parties Accrued Liabilities, Current Accrued liabilities Liabilities, Current Total current liabilities Notes Payable, Current Note payable, net of discount Notes Payable, Noncurrent Note payable, net of discount Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $1.00 par value: 5,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2018 and December 31, 2017 Common Stock, Value, Issued Common stock, $.01 par value: 170,0000,000 shares authorized at September 30, 2018 and December 31, 2017; 93,480,493 shares and 69,901,625 shares issued at September 30, 2018 and December 31, 2017, respectively Additional Paid in Capital Additional paid-in capital Treasury Stock, Value Treasury stock, at cost: 79,545 shares held at September 30, 2018 and December 31, 2017 Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' equity Balance Balance Common Stock To Be Issued Value Common stock to be issued for 186,567 shares The aggregate value of common stock to be issued. Liabilities and Equity Total liabilities and stockholders' equity Other Liabilities, Noncurrent Other liabilities Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Treasury Stock, Shares Treasury stock, shares held Common Stock To Be Issued Common stock to be issued Total number of common shares to be issued. Income Statement [Abstract] Equity Components [Axis] Equity Component [Domain] Revenues [Abstract] Revenues: Revenues Product sales Costs and Expenses [Abstract] Costs and expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Research and Development in Process Acquired in-process research and development Costs and Expenses Costs and expenses Interest Income (Expense), Net Interest (income) expense, net Increase (Decrease) in Derivative Liabilities Change in fair value of contingent rights Change in fair value of contingent rights Net Income (Loss) Attributable to Parent Net loss Net loss Earnings Per Share, Basic and Diluted Net loss per share (basic and diluted) Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average number of common shares outstanding (basic and diluted) Statement of Comprehensive Income [Abstract] Comprehensive loss: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Foreign currency translation adjustment Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive loss Other Nonoperating Expense Other expense Statement of Stockholders' Equity [Abstract] Preferred Stock [Member] Common Stock [Member] Treasury Stock [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss [Member] Retained Earnings [Member] Accumulated Deficit [Member] Common Stock To Be Issued [Member] Common Stock to Be Issued [Member] Represent the Stock to be issued. Shares, Outstanding Balance (in Shares) Balance (in shares) Cumulative Effect on Retained Earnings, Net of Tax Cumulative effect adjustment due to the adoption of ASU 2016-01 Stock Issued During Period, Value, Other Issuance of common stock and warrants pursuant to financing agreements Stock Issued During Period, Shares, Other Issuance of common stock and warrants pursuant to financing agreements (in shares) Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock for options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of common stock for options exercised (in shares) Exercised - Number of Options Stock Issued During Period Value Warrants Exercised1 Issuance of common stock from exercise of warrants Value of stock issued as a result of the exercise of stock options. Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Exercises in Period Issuance of common stock from exercise of warrants (in Shares) Number of warrants exercised during the current period. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Stock issuance costs Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation expense Other Comprehensive Income (Loss), Foreign Currency Translation Gain (Loss) Arising During Period, Tax Foreign currency translation adjustment Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Stock option grants surrendered Stockholders Equity Shares to be Issued Common stock to be issued The aggregate value of Stockholders' Equity, shares to be issued. Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Amortization of Intangible Assets Amortization of intangible assets Share-based Compensation Stock-based compensation expense Share-based compensation expense Unrealized Gain (Loss) on Investments Unrealized loss on equity investment Paid-in-Kind Interest Non-cash interest Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Related Parties Payable to related party Increase (Decrease) in Accrued Liabilities Accrued liabilities Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Loss on disposal of assets Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Intangible Assets Acquisition of Abbreviated New Drug Applications and related items Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Proceeds from Sale of Property, Plant, and Equipment Proceeds from sale of furniture and equipment Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Payments of Stock Issuance Costs Stock issuance costs Proceeds from Issuance of Common Stock and Warrants Proceeds from sale of common stock and warrants The cash inflow from the additional capital contribution to the entity through the issuance of common stock and warrants. Proceeds from Stock Options Exercised Proceeds from exercise of stock options Proceeds from Warrant Exercises Proceeds from exercise of stock warrants Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Proceeds From Sale Of Common Stock To Be Issued Proceeds from sale of common stock to be issued The cash inflow from sale of common stock to be issued. Payments Related to Tax Withholding for Share-based Compensation Cash paid to satisfy tax withholding obligations Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rate changes on cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in cash and cash equivalents Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Accounting [Text Block] Basis of Accounting [Text Block] Acquisition of Abbreviated New Drug Applications [Abstract] Acquisition of Abbreviated New Drug Applications [Text Block] The entire disclosure for the acquisition of abbreviated new drug applications. Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Disclosure [Text Block] Foreign Currency [Abstract] Foreign Currency Disclosure [Text Block] Schedule of Investments [Abstract] Investment Holdings, Schedule of Investments [Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Research and Development [Abstract] Research, Development, and Computer Software Disclosure [Text Block] License Arrangements Disclosure [Abstract] License Arrangements Disclosure [Text Block] The entire disclosure for license arrangements. Debt Disclosure [Abstract] Debt Disclosure [Text Block] Stockholders' Equity Note [Abstract] Stockholders' Equity Note Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Tax Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events [Text Block] Schedule Of Finite Lived Intangible Assets and Active Pharmaceutical Ingredient Inventory [Table Text Block] Schedule Of Finite Lived Intangible Assets and API Inventory [Table Text Block] Tabular disclosure of assets, schedule of finite lived intangible assets and active pharmaceutical ingredient (API) inventory . Finite-lived Intangible Assets Amortization Expense [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule Of Warrant Activity [Table Text Block] Tabular disclosure related to the share based warrant activity. Shedule of Description of Business and Basis of Presentation [Table] CASI China [Member] Scenario [Axis] Scenario, Unspecified [Domain] Stock Issued [Axis] Stock Issued [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Sale of Stock [Axis] Sale of Stock [Domain] Private Placement [Member] Private Placement [Member] Related Party [Axis] Related Party [Domain] Investor [Member] Investors [Member] Description of Business and Basis of Presentation [Line Items] Percentage Of Ownership Interest In Non Stock Subsidiary Percentage of ownership interest held by the parent entity in the non stock subsidiary. EX-101.PRE 11 casi-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2018	Nov. 07, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Entity Registrant Name	CASI Pharmaceuticals, Inc.
Entity Central Index Key	0000895051
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Trading Symbol	CASI
Entity Common Stock, Shares Outstanding		93,587,515
Entity Emerging Growth Company	false
Entity Small Business	true

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 98,867,087	$ 43,489,935
Investments, at fair value	1,165,046	0
Prepaid expenses and other	1,343,667	322,493
Total current assets	101,375,800	43,812,428
Property and equipment, net	1,594,189	1,046,514
Other assets	228,431	242,023
Intangible assets, net	17,110,422	0
Total assets	120,308,842	45,100,965
Current liabilities:
Accounts payable	1,740,611	2,087,770
Payable to related parties	2,880,000	2,228,366
Accrued liabilities	800,975	745,961
Note payable, net of discount	1,499,285	0
Total current liabilities	6,920,871	5,062,097
Note payable, net of discount	0	1,498,754
Other liabilities	66,567	0
Total liabilities	6,987,438	6,560,851
Commitments and contingencies
Stockholders' equity:
Preferred stock, $1.00 par value: 5,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2018 and December 31, 2017	0	0
Common stock, $.01 par value: 170,0000,000 shares authorized at September 30, 2018 and December 31, 2017; 93,480,493 shares and 69,901,625 shares issued at September 30, 2018 and December 31, 2017, respectively	934,804	699,015
Common stock to be issued for 186,567 shares	1,000,000	0
Additional paid-in capital	590,322,314	498,577,372
Treasury stock, at cost: 79,545 shares held at September 30, 2018 and December 31, 2017	(8,034,244)	(8,034,244)
Accumulated other comprehensive loss	(1,224,748)	0
Accumulated deficit	(469,676,722)	(452,702,029)
Total stockholders' equity	113,321,404	38,540,114
Total liabilities and stockholders' equity	$ 120,308,842	$ 45,100,965

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets [Parenthetical] - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Preferred Stock, Par or Stated Value Per Share	$ 1.00	$ 1.00
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	1,700,000,000	1,700,000,000
Common stock, shares issued	93,480,493	69,901,625
Treasury stock, shares held	79,545	79,545
Common stock to be issued	186,567

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Product sales	$ 0	$ 0	$ 0	$ 0
Costs and expenses:
Research and development	1,806,222	970,989	5,232,925	3,747,683
General and administrative	6,904,800	625,878	12,250,269	1,961,463
Acquired in-process research and development	0	0	686,998	0
Costs and expenses	8,711,022	1,596,867	18,170,192	5,709,146
Interest (income) expense, net	(10,652)	546	(30,453)	476
Other expense	55,941	0	67,266	0
Change in fair value of contingent rights	0	16,110	0	12,665
Net loss	$ (8,756,311)	$ (1,613,523)	$ (18,207,005)	$ (5,722,287)
Net loss per share (basic and diluted)	$ (0.10)	$ (0.03)	$ (0.22)	$ (0.10)
Weighted average number of common shares outstanding (basic and diluted)	86,953,611	60,196,574	81,457,085	60,196,574
Comprehensive loss:
Net loss	$ (8,756,311)	$ (1,613,523)	$ (18,207,005)	$ (5,722,287)
Foreign currency translation adjustment	(685,106)	0	(1,224,748)	0
Total comprehensive loss	$ (9,441,417)	$ (1,613,523)	$ (19,431,753)	$ (5,722,287)

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Stockholders' Equity - 9 months ended Sep. 30, 2018 - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Common Stock to Be Issued [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2017	$ 38,540,114	$ 0	$ 699,015	$ (8,034,244)	$ 498,577,372		$ 0	$ (452,702,029)
Balance (in Shares) at Dec. 31, 2017		0	69,822,080
Cumulative effect adjustment due to the adoption of ASU 2016-01	1,232,312	$ 0	$ 0	0	0	0	0	1,232,312
Issuance of common stock and warrants pursuant to financing agreements	86,990,216	$ 0	$ 223,850	0	86,766,366	0	0	0
Issuance of common stock and warrants pursuant to financing agreements (in shares)		0	22,385,038
Issuance of common stock for options exercised	257,948	$ 0	$ 1,397	0	256,551	0	0	0
Issuance of common stock for options exercised (in shares)		0	139,683
Stock option grants surrendered	(117,194)	$ 0	$ 0	0	(117,194)	0	0	0
Issuance of common stock from exercise of warrants	2,088,035	$ 0	$ 10,542	0	2,077,493	0	0	0
Issuance of common stock from exercise of warrants (in Shares)		0	1,054,147
Common stock to be issued	1,000,000	$ 0	$ 0	0	0	1,000,000	0	0
Stock issuance costs	(755,767)	0	0	0	(755,767)	0	0	0
Stock-based compensation expense	3,517,493	0	0	0	3,517,493	0	0	0
Foreign currency translation adjustment	(1,224,748)	0	0	0	0	0	(1,224,748)	0
Net loss	(18,207,005)	0	0	0	0	0	0	(18,207,005)
Balance at Sep. 30, 2018	$ 113,321,404	$ 0	$ 934,804	$ (8,034,244)	$ 590,322,314	$ 1,000,000	$ (1,224,748)	$ (469,676,722)
Balance (in shares) at Sep. 30, 2018		0	93,400,948

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (18,207,005)	$ (5,722,287)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	249,738	69,420
Loss on disposal of assets	5,427
Amortization of intangible assets	944,563	0
Stock-based compensation expense	3,517,493	516,237
Acquired in-process research and development	686,998	0
Unrealized loss on equity investment	67,266	0
Non-cash interest	531	5,607
Change in fair value of contingent rights	0	12,665
Changes in operating assets and liabilities:
Prepaid expenses and other	(610,795)	(119,686)
Accounts payable	(326,535)	139,339
Payable to related party	651,634	0
Accrued liabilities	146,149	51,694
Net cash used in operating activities	(12,874,536)	(5,047,011)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of furniture and equipment	599	0
Purchases of property and equipment	(861,667)	(405,849)
Acquisition of Abbreviated New Drug Applications and related items	(19,171,956)	0
Net cash used in investing activities	(20,033,024)	(405,849)
CASH FLOWS FROM FINANCING ACTIVITIES
Stock issuance costs	(755,767)	0
Proceeds from sale of common stock and warrants	86,990,216	0
Proceeds from sale of common stock to be issued	1,000,000	0
Proceeds from exercise of stock options	257,948	0
Cash paid to satisfy tax withholding obligations	(117,194)	0
Proceeds from exercise of stock warrants	2,088,035	0
Net cash provided by financing activities	89,463,238	0
Effect of exchange rate changes on cash and cash equivalents	(1,178,526)	0
Net increase (decrease) in cash and cash equivalents	55,377,152	(5,452,860)
Cash and cash equivalents at beginning of period	43,489,935	27,092,928
Cash and cash equivalents at end of period	$ 98,867,087	$ 21,640,068

XML 18 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Accounting [Text Block]

Basis of Presentation

Liquidity Risks and Management’s Plans

XML 19 R8.htm IDEA: XBRL DOCUMENT

Acquisition of Abbreviated New Drug Applications

9 Months Ended

Sep. 30, 2018

Acquisition of Abbreviated New Drug Applications [Abstract]

Acquisition of Abbreviated New Drug Applications [Text Block]

Acquisition of Abbreviated New Drug Applications

ANDAs	$	18,608,000
API		564,000
Total value	$	19,172,000

XML 20 R9.htm IDEA: XBRL DOCUMENT

Intangible Assets

9 Months Ended

Sep. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets Disclosure [Text Block]

Intangible Assets

Asset		Gross Value				Accumulated Amortization				Estimated useful lives
ANDAs		$	18,054,985			$	(944,563	)		13 years

Expected future amortization expense is as follows for the years ending December 31:

2018 (remaining three months)	$	347,212
2019		1,388,845
2020		1,388,845
2021		1,388,845
2022		1,388,845
2023 and thereafter		11,207,830

XML 21 R10.htm IDEA: XBRL DOCUMENT

Foreign Currency Translation

9 Months Ended

Sep. 30, 2018

Foreign Currency [Abstract]

Foreign Currency Disclosure [Text Block]

Foreign Currency Translation

XML 22 R11.htm IDEA: XBRL DOCUMENT

Investments

9 Months Ended

Sep. 30, 2018

Schedule of Investments [Abstract]

Investment Holdings, Schedule of Investments [Text Block]

Investments

XML 23 R12.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Sep. 30, 2018

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

Inventories

XML 24 R13.htm IDEA: XBRL DOCUMENT

Research and Development

9 Months Ended

Sep. 30, 2018

Research and Development [Abstract]

Research, Development, and Computer Software Disclosure [Text Block]

Research and Development

XML 25 R14.htm IDEA: XBRL DOCUMENT

License Arrangements

9 Months Ended

Sep. 30, 2018

License Arrangements Disclosure [Abstract]

License Arrangements Disclosure [Text Block]

License Arrangements

EVOMELA

(melphalan) for Injection (“EVOMELA”);

MARQIBO

(vinCRIStine sulfate LIPOSOME injection) (“MARQIBO”); and

ZEVALIN

(ibritumomab tiuxetan) (“ZEVALIN”).

The Company is in various stages of the regulatory and development process to obtain marketing approval for EVOMELA

, MARQIBO

, and ZEVALIN

in its territorial region, with ZEVALIN

commercially available in Hong Kong. In January 2016, the China Food and Drug Administration (CFDA) accepted for review the Company’s import drug registration application for MARQIBO

and has completed the quality testing phase of the regulatory process and is currently in technical review by Center for Drug Evaluation (CDE) of the CFDA as part of the regulatory process. On March 10, 2016, Spectrum received notification from the FDA of the grant of approval of its New Drug Application (NDA) for EVOMELA

primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. In December 2016, the CFDA accepted for review the Company’s import drug registration application for EVOMELA

and in 2017 has granted priority review of the import drug registration clinical trial application (CTA). EVOMELA

has completed the quality testing phase of the regulatory process, as well as the technical review by CDE of the CFDA, and was evaluated under a CFDA CDE Advisory Committee meeting held in the second quarter of 2018 followed by a series of standard questions from the CFDA related to EVOMELA

drug product production which usually reflects the final stage of CFDA assessment before approval based on the Import Drug Approval registration pathway. CASI is diligently working with Spectrum and their vendors to address the questions and submit the requested documents. In 2017, the CFDA accepted for review the Company’s import drug registration for ZEVALIN

including both the antibody kit and the radioactive Yttrium-90 component. ZEVALIN

is currently under the quality testing phase of the regulatory process by National Institute for Food and Drug Control (NIFDC) as well as the technical review by CDE of the CFDA.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note Payable

9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

Note Payable

XML 27 R16.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2018

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

10.

Stockholders’ Equity

Securities Purchase Agreements

Common Stock Sales Agreement

XML 28 R17.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

9 Months Ended

Sep. 30, 2018

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

11.

Net Loss Per Share

XML 29 R18.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation and Warrants

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

12.

Stock-Based Compensation and Warrants

	Nine Month Period ended September 30,
	2018		2017
Research and development	$	232,230	$	225,342
General and administrative		3,285,263		290,895
Share-based compensation expense	$	3,517,493	$	516,237
Net share-based compensation expense, per common share:
Basic and diluted	$	0.04	$	0.01

	Nine Month Period ended September 30,
	2018			2017
Expected volatility		78.79	%		78.92	%
Risk free interest rate		2.80	%		1.97	%
Expected term of option		5.77 years			6.34 years
Expected dividend yield		0.00	%		0.00	%

The weighted average fair value of stock options granted during the nine-month periods ended September 30, 2018 and 2017 were $4.51 and $0.73, respectively.

A summary of the Company's stock option plans and of changes in options outstanding under the plans during the nine-month period ended September 30, 2018 is as follows:

	Number of Options			Weighted Average Exercise Price
Outstanding at January 1, 2018		11,585,315		$	1.42
Exercised		(156,283	)	$	1.65
Granted		7,286,000		$	4.02
Expired		(279,970	)	$	1.50
Forfeited		(50,130	)	$	3.28
Outstanding at September 30, 2018		18,384,932		$	2.44
Exercisable at September 30, 2018		8,753,696		$	1.59

Warrants

Warrants issued generally expire after 2-5 years from the date of issuance. Stock warrant activity is as follows:

	Number of Warrants			Weighted Average Exercise Price
Outstanding at January 1, 2018		6,264,016		$	2.23
Issued		8,215,739		$	4.56
Exercised		(1,054,147	)	$	1.98
Expired		-		$	-
Outstanding at September 30, 2018		13,425,608		$	3.68
Exercisable at September 30, 2018		11,382,701		$	3.04

Cash received from warrants exercised during the nine months ended September 30, 2018 was $2,088,035. There were no warrants exercised during the nine months ended September 30, 2017.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2018

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

13.

Income Taxes

XML 31 R20.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Sep. 30, 2018

14.

Related Party Transactions

The Company has supply agreements with Spectrum for the purchase of EVOMELA

, MARQIBO

, and ZEVALIN

in China for quality testing purposes to support CASI’s application for import drug registration and for commercialization purposes. The former CEO of Spectrum is also a member of CASI’s Board and Spectrum is the Company’s largest shareholder. All amounts payable to Spectrum for material purchases have been paid as of September 30, 2018. There were no materials purchased from Spectrum for the nine months ended September 30, 2018. In April and June 2017, under supply agreements with Spectrum, the Company received shipments of EVOMELA

and MARQIBO

, respectively, in China for quality testing purposes to support CASI’s application for import drug registration. The total cost of the materials was approximately $477,000, which is included in research and development expense for the nine months ended September 30, 2017.

Emerging Technology Partners, LLC (“ETP”) incurred approximately $

million of expenses for due diligence and related services (the “Services”) for certain

business development activities. The Company benefited by having access to the results of those Services and did not have to incur such expense on its own. The Company’s Executive Chairman is the founder and managing member of ETP. The Company’s Audit Committee authorized and directed the Company to reimburse ETP $1.5 million for the expenses incurred in connection with the Services which is included as general and administrative expenses in the accompanying condensed consolidated statement of operations for the three and nine month periods ended September 30, 2018. The amount payable to ETP totaling $1.5 million is included in “payable to related parties” in the accompanying condensed consolidated balance sheet as of September 30, 2018 and was paid in October 2018.

XML 32 R21.htm IDEA: XBRL DOCUMENT

New Accounting Pronouncements

9 Months Ended

Sep. 30, 2018

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

New Accounting Pronouncements and Changes in Accounting Principles [Text Block]

15.

New Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02,

Leases

(Topic 842). ASU 2016-02 supersedes existing lease guidance, including Accounting Standards Codification (ASC) 840 -

Leases

. Among other things, the new standard requires recognition of a right-of-use asset and liability for future lease payments for contracts that meet the definition of a lease. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted. The standard must be applied using a modified retrospective approach. The Company is completing its evaluation of the effect of the adoption of this ASU and tentatively expects that the adoption will result in an increase to both assets and liabilities on the consolidated balance sheet, with no significant effects on operating results.

In July 2018, the FASB issued ASU 2018-11,

Leases (Topic 842) Targeted Improvements

, which offers a transition option to entities adopting the new lease standard. Under the transition option, entities can recognize a cumulative effect adjustment to the opening balance of retained earnings of the year in which the new lease standard is adopted, rather than in the earliest period presented in their financial statements. The Company is currently evaluating the effect the adoption of this ASU will have on its consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-01,

Clarifying the Definition of a Business

(Topic 805). The amendments in the update provide a screen to determine when a set is not a business. If the screen is not met, the amendments in the update (1) require that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. The amendments provide a framework to assist entities in evaluating whether both an input and a substantive process are present. Lastly, the amendments in the update narrow the definition of the term output so that the term is consistent with how outputs are described in Topic 606. The ASU is effective for annual periods and interim periods within those annual periods beginning after December 15, 2017; earlier adoption is permitted under certain criteria. The Company adopted this ASU on January 1, 2018. While this ASU did not have a material effect on the Company’s financial statements on the date of adoption, the Company did follow the new guidance in determining that its acquisition of ANDAs from Sandoz, Inc. in January 2018 was an asset acquisition (see Note 2).

In May 2017, the FASB issued ASU 2017-09,

Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting

. ASU 2017-09 provides clarification on when modification accounting should be used for changes to the terms or conditions of a share-based payment award. This ASU does not change the accounting for modifications but clarifies that modification accounting guidance should only be applied if there is a change to the value, vesting conditions, or award classification and would not be required if the changes are considered non-substantive. This ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted ASU 2017-09 in the first quarter of 2018 and the adoption of this ASU did not have a material effect on the consolidated financial statements.

In June 2018, the FASB issued ASU 2018-07,

Compensation-Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting

which includes updated guidance for share-based payment awards issued to non-employees. The updated standard aligns the accounting for share-based payment awards for non-employees with employees, except for guidance related to the attribution of compensation costs for non-employees. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods for public business entities, with early adoption permitted. The Company is considering early adopting this standard in the fourth quarter of 2018. The adoption of this ASU is not expected to have a material impact on the Company’s consolidated financial statements.

There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows.

XML 33 R22.htm IDEA: XBRL DOCUMENT

Commitments

9 Months Ended

Sep. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

16.

Commitments

In 2018, the Company entered into purchase obligation commitments for EVOMELA

from Spectrum for approximately $9.2 million.

XML 34 R23.htm IDEA: XBRL DOCUMENT

Subsequent Event

9 Months Ended

Sep. 30, 2018

Subsequent Events [Abstract]

Subsequent Events [Text Block]

17.

Subsequent Event

In October 2018, the Company entered into an agreement with Laurus Labs Limited (

“Laurus”

), a company organized under the Laws of India, pursuant to which the Company will acquire from Laurus one U.S. FDA-approved abbreviated new drug application for tenofovir disoproxil fumarate (TDF ANDA), which is indicated for the treatment of hepatitis B virus. The aggregate purchase price for the TDF ANDA was $3 million, with an upfront payment of $700,000, paid in October 2018, and $2.3 million to be paid upon completion of certain milestones.

XML 35 R24.htm IDEA: XBRL DOCUMENT

Acquisition of Abbreviated New Drug Applications (Tables)

9 Months Ended

Sep. 30, 2018

Acquisition of Abbreviated New Drug Applications [Abstract]

Schedule Of Finite Lived Intangible Assets and API Inventory [Table Text Block]

ANDAs	$	18,608,000
API		564,000
Total value	$	19,172,000

XML 36 R25.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Finite-lived Intangible Assets Amortization Expense [Table Text Block]

Net finite-lived intangible assets at September 30, 2018 consists of the following:

Asset		Gross Value				Accumulated Amortization				Estimated useful lives
ANDAs		$	18,054,985			$	(944,563	)		13 years

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Expected future amortization expense is as follows for the years ending December 31:

2018 (remaining three months)	$	347,212
2019		1,388,845
2020		1,388,845
2021		1,388,845
2022		1,388,845
2023 and thereafter		11,207,830

XML 37 R26.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation and Warrants (Tables)

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	Nine Month Period ended September 30,
	2018		2017
Research and development	$	232,230	$	225,342
General and administrative		3,285,263		290,895
Share-based compensation expense	$	3,517,493	$	516,237
Net share-based compensation expense, per common share:
Basic and diluted	$	0.04	$	0.01

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Following are the weighted-average assumptions used in valuing the stock options granted to employees during the nine-month periods ended September 30, 2018 and 2017:

	Nine Month Period ended September 30,
	2018			2017
Expected volatility		78.79	%		78.92	%
Risk free interest rate		2.80	%		1.97	%
Expected term of option		5.77 years			6.34 years
Expected dividend yield		0.00	%		0.00	%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of the Company's stock option plans and of changes in options outstanding under the plans during the nine-month period ended September 30, 2018 is as follows:

	Number of Options			Weighted Average Exercise Price
Outstanding at January 1, 2018		11,585,315		$	1.42
Exercised		(156,283	)	$	1.65
Granted		7,286,000		$	4.02
Expired		(279,970	)	$	1.50
Forfeited		(50,130	)	$	3.28
Outstanding at September 30, 2018		18,384,932		$	2.44
Exercisable at September 30, 2018		8,753,696		$	1.59

Schedule Of Warrant Activity [Table Text Block]

Warrants issued generally expire after 2-5 years from the date of issuance. Stock warrant activity is as follows:

	Number of Warrants			Weighted Average Exercise Price
Outstanding at January 1, 2018		6,264,016		$	2.23
Issued		8,215,739		$	4.56
Exercised		(1,054,147	)	$	1.98
Expired		-		$	-
Outstanding at September 30, 2018		13,425,608		$	3.68
Exercisable at September 30, 2018		11,382,701		$	3.04

XML 38 R27.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Details Textual) - USD ($)	1 Months Ended	2 Months Ended	9 Months Ended
Basis of Presentation (Details Textual) - USD ($)	Sep. 24, 2018	Oct. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Description of Business and Basis of Presentation [Line Items]
Retained Earnings (Accumulated Deficit)			$ (469,676,722)	$ (452,702,029)
Percentage Of Ownership Interest In Non Stock Subsidiary			100.00%
Stock Issued During Period, Shares, New Issues	6,809,699
Investor [Member]
Description of Business and Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues			15,432,091
Stock to be issued Shares	9,048,504
Number of Warrants to Purchase Common Stock Issued During the Period	2,042,907		6,172,832
Future Proceeds From Issuance Of Common Stock Gross			$ 11,000,000
Warrants to be issued	2,714,548
Private Placement [Member]
Description of Business and Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock and Warrants Gross	$ 36,500,000		50,000,000
Private Placement [Member] \| Investor [Member]
Description of Business and Basis of Presentation [Line Items]
Stock and Warrants to be Issued Value	$ 48,500,000
Subsequent Event [Member] \| Investor [Member]
Description of Business and Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock and Warrants Gross		$ 37,500,000
CASI China [Member]
Description of Business and Basis of Presentation [Line Items]
Cash			$ 15,200,000

XML 39 R28.htm IDEA: XBRL DOCUMENT

Acquisition of Abbreviated New Drug Applications (Details)	9 Months Ended
	Sep. 30, 2018 USD ($)
Purchase Price For The Assets Acquired	$ 19,172,000
Abbreviated new drug applications [Member]
Purchase Price For Finite-lived Intangible Assets Acquired	18,608,000
Active pharmaceutical ingredient [Member]
Purchase Price For Raw Materials Inventory Acquired	$ 564,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

Acquisition of Abbreviated New Drug Applications (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Research and Development in Process		$ 0	$ 0	$ 686,998	$ 0
Finite-Lived Intangible Asset, Useful Life				13 years
Payments to Acquire Intangible Assets	$ 18,000,000			$ 19,171,956	$ 0
Abbreviated new drug applications [Member]
Research and Development in Process				553,000
Active pharmaceutical ingredient [Member]
Research and Development in Process				134,000
Accounting Standards Update 2017-01 [Member]
Asset Acquisition Transaction Costs				$ 1,200,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details)	9 Months Ended
Intangible Assets (Details)	Sep. 30, 2018 USD ($)
Estimated useful lives	13 years
Abbreviated new drug applications [Member]
Gross Value	$ 18,054,985
Accumulated Amortization	$ (944,563)
Estimated useful lives	13 years

XML 42 R31.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details 1)	Sep. 30, 2018 USD ($)
2018 (remaining three months)	$ 347,212
2019	1,388,845
2020	1,388,845
2021	1,388,845
2022	1,388,845
2023 and thereafter	$ 11,207,830

XML 43 R32.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
Intangible Assets (Details Textual) - USD ($)	Jan. 31, 2018	Sep. 30, 2018	Sep. 30, 2017
Finite-Lived Intangible Asset, Useful Life		13 years
Payments to Acquire Intangible Assets	$ 18,000,000	$ 19,171,956	$ 0
Accounting Standards Update 2017-01 [Member]
Asset Acquisition Transaction Costs		$ 1,200,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

Investments (Details Textual) - USD ($)	9 Months Ended
Investments (Details Textual) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Short-term Investments	$ 1,165,046	$ 0
Cumulative Effect on Retained Earnings, Net of Tax	1,232,312
Fair Value, Inputs, Level 1 [Member]
Short-term Investments	$ 1,200,000

XML 45 R34.htm IDEA: XBRL DOCUMENT

Inventories (Details Textual)	Sep. 30, 2018 USD ($)
Raw Materials [Member]
Inventory, Raw Materials, Net of Reserves	$ 430,000

XML 46 R35.htm IDEA: XBRL DOCUMENT

Note Payable (Details Textual) - USD ($)	9 Months Ended
Note Payable (Details Textual) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Notes Payable [Line Items]
Amortization of Debt Discount (Premium)	$ 531	$ 5,607
Spectrum Pharmaceuticals [Member]
Notes Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	0.50%
Debt Instrument Initial Discount Upon Issuance	$ 136,000
Debt Instrument, Face Amount	$ 1,500,000

XML 47 R36.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
Stockholders' Equity (Details Textual) - USD ($)	Sep. 24, 2018	Mar. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Feb. 23, 2018	Dec. 31, 2017
Stock Issued During Period, Shares, New Issues	6,809,699
Price Per Share and Warrant		$ 3.24
Remaining Dollar Amount Available Under Sales Agreement					$ 24,500,000
Accounts Payable, Related Parties, Current			$ 2,880,000		2,880,000			$ 2,228,366
General and Administrative Expense			6,904,800	$ 625,878	12,250,269	$ 1,961,463
Board of Directors Chairman [Member]
Accounts Payable, Related Parties, Current			$ 1,380,000		1,380,000
General and Administrative Expense					1,380,000
Payment To Be Made For Services Rendered					1,460,000
Executive Officer [Member]
General and Administrative Expense					120,000
Payment To Be Made For Services Rendered					$ 480,000
Investors [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		3.69
Stock Issued During Period, Shares, New Issues					15,432,091
Price Per Share and Warrant	$ 5.36
Number of Warrants to Purchase Common Stock Issued During the Period	2,042,907				6,172,832
Future Proceeds From Issuance Of Common Stock Gross					$ 11,000,000
Stock to be issued Shares	9,048,504
Warrants to be issued	2,714,548
Investors [Member] \| Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.19
H.C. Wainwright Co., LLC [Member] \| Maximum [Member]
Aggregate Sales Price							$ 25,000,000
Securities Purchase Agreements [Member]
Fair Value Assumptions Fair Value	$ 2.98	$ 2.44
Fair Value Of Warrants Issued	$ 6,087,863				15,062,000
Securities Purchase Agreements [Member] \| Measurement Input, Expected Term [Member]
Fair Value Assumptions Term	3 years	5 years
Securities Purchase Agreements [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Fair Value Assumptions rate	2.89%	2.69%
Securities Purchase Agreements [Member] \| Measurement Input, Price Volatility [Member]
Fair Value Assumptions rate	88.39%	75.40%
Private Placement [Member]
Stock Issued During Period, Value, New Issues					50,000,000
Proceeds from Issuance of Common Stock and Warrants Gross	$ 36,500,000				50,000,000
Private Placement [Member] \| Investors [Member]
Stock and Warrants to be Issued Value	$ 48,500,000
Second Closing [Member]
Proceeds for Common Stock to be issued					$ 1,000,000
Sales Agreement [Member]
Net Proceeds From Issuance Of Common Stock		$ 475,000
Stock Issued During Period, Shares, New Issues		143,248

XML 48 R37.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Details Textual)	9 Months Ended
Net Loss Per Share (Details Textual)	Sep. 30, 2018 shares
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	18,384,932
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	13,425,608

XML 49 R38.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation and Warrants (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 3,517,493	$ 516,237
Net share-based compensation expense, per common share:
Basic and diluted (in dollars per share)	$ 0.04	$ 0.01
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 232,230	$ 225,342
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 3,285,263	$ 290,895

XML 50 R39.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation and Warrants (Details 1)	9 Months Ended
Stock-Based Compensation and Warrants (Details 1)	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	78.79%	78.92%
Risk free interest rate	2.80%	1.97%
Expected term of option	5 years 9 months 7 days	6 years 4 months 2 days
Expected dividend yield	0.00%	0.00%

XML 51 R40.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation and Warrants (Details 2) - Employee Stock Option [Member]	9 Months Ended
	Sep. 30, 2018 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding - Number of Options, Beginning Balance \| shares	11,585,315
Exercised - Number of Options \| shares	(156,283)
Granted - Number of Options \| shares	7,286,000
Expired - Number of Options \| shares	(279,970)
Forfeited - Number of Options \| shares	(50,130)
Outstanding - Number of Options, Ending Balance \| shares	18,384,932
Exercisable - Number of Options \| shares	8,753,696
Outstanding - Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 1.42
Exercised - Weighted Average Exercise Price \| $ / shares	1.65
Granted - Weighted Average Exercise Price \| $ / shares	4.02
Expired - Weighted Average Exercise Price \| $ / shares	1.50
Forfeited - Weighted Average Exercise Price \| $ / shares	3.28
Outstanding - Weighted Average Exercise Price, Ending Balance \| $ / shares	2.44
Exercisable - Weighted Average Exercise Price \| $ / shares	$ 1.59

XML 52 R41.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation and Warrants (Details 3) - Warrant [Member]	9 Months Ended
	Sep. 30, 2018 $ / shares shares
Outstanding at Number of Warrants, Beginning Balance \| shares	6,264,016
Issued Number of Warrants \| shares	8,215,739
Exercised Number of Warrants \| shares	(1,054,147)
Expired Number of Warrants \| shares	0
Outstanding at Number of Warrants, Ending Balance \| shares	13,425,608
Exercisable Number of Warrants \| shares	11,382,701
Outstanding Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 2.23
Issued Weighted Average Exercise Price \| $ / shares	4.56
Exercised Weighted Average Exercise Price \| $ / shares	1.98
Expired Weighted Average Exercise Price \| $ / shares	0
Outstanding Weighted Average Exercise Price, Ending Balance \| $ / shares	3.68
Exercisable Weighted Average Exercise Price \| $ / shares	$ 3.04

XML 53 R42.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation and Warrants (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Mar. 13, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 4.51	$ 0.73
Share-based Compensation	$ 3,517,493	$ 516,237
Proceeds from Stock Options Exercised	257,948	0
Proceeds from Warrant Exercises	$ 2,088,035	$ 0
Executive Chairman [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number			1,000,000
Executive Chairman [Member] \| Performance Based Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number			4,000,000
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Expire Terms	5 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Expire Terms	2 years
Long Term Incentive Plan2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	6,878,610
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	18,384,932
Long Term Incentive Plan2011 [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 8.23
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	20,230,000
Long Term Incentive Plan2011 [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 0.86
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	14,230,000

XML 54 R43.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Textual) $ in Millions	Dec. 31, 2017 USD ($)
Income Tax Contingency [Line Items]
Unrecognized Tax Benefits	$ 3.2

XML 55 R44.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
Related Party Transactions (Details Textual) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Research and Development Expense	$ 1,806,222	$ 970,989	$ 5,232,925	$ 3,747,683
General and Administrative Expense	6,904,800	$ 625,878	12,250,269	1,961,463
Accounts Payable, Related Parties, Current	2,880,000		2,880,000		$ 2,228,366
Spectrum [Member]
Research and Development Expense				$ 477,000
Emerging Technology Partners LLC [Member]
General and Administrative Expense	1,500,000		1,500,000
Accounts Payable, Related Parties, Current	1,500,000		$ 1,500,000
Business Development	$ 3,000,000

XML 56 R45.htm IDEA: XBRL DOCUMENT

Commitments (Details Textual)	10 Months Ended
Commitments (Details Textual)	Oct. 31, 2018 USD ($)	Nov. 01, 2018 ft²	Dec. 31, 2017 USD ($)
Operating Lease, Future Minimum Payments, in Current Year			$ 139,300
Operating Lease, Future Minimum Payments, in Two Years			557,200
Operating Lease, Future Minimum Payments, in Three Years			557,200
Operating Lease, Future Minimum Payments, in Four Years			139,300
Lease In China [Member]
Operating Lease, Future Minimum Payments, in Current Year			90,600
Operating Lease, Future Minimum Payments, in Two Years			418,000
Operating Lease, Future Minimum Payments, in Three Years			418,000
Operating Lease, Future Minimum Payments, in Four Years			383,100
Lease In Rockville [Member]
Operating Lease, Future Minimum Payments, in Current Year			8,400
Operating Lease, Future Minimum Payments, in Two Years			50,500
Operating Lease, Future Minimum Payments, in Three Years			138,600
Operating Lease, Future Minimum Payments, in Four Years			142,700
Operating Leases, Future Minimum Payments, in Five Years			$ 85,700
Subsequent Event [Member]
Purchase obligation to purchase materials	$ 9,200,000
Land Subject to Ground Leases \| ft²		6,068

XML 57 R46.htm IDEA: XBRL DOCUMENT

Subsequent Event (Details Textual) - Subsequent Event [Member]	1 Months Ended
	Oct. 31, 2018 USD ($)
Purchase Price Of Drug	$ 3,000,000
Upfront Payment For Drug	700,000
Future Obligations To Be Paid	$ 2,300,000

EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( &Q0;DT?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ ;%!N32?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " !L4&Y-D%J:?>X K @ $0 &1O8U!R;W!S+V-O M&ULS9+!:L,P#(9?9?B>*$[*&";UI:.G#@8K;.QF;+4UBQUC:R1]^R5> MFS*V!]C1TN]/GT"M#D+W$9]C'S"2Q70WNLXGH<.:G8B" $CZA$ZE,1@M(?ZHA05]4]."1E%"F8@458B$RV1@L=45$?+WBC%WSXC%V&&0W8 MH4-/"7C)@UI]Y+7+:Q/I+S&Z5>R@LX!U^PZ^;79/.ZW3-85?R@X+_AJSRM1U:)9O<^N M/_QNPJXW]F#_L?%54+;PZR[D%U!+ P04 " !L4&Y-F5R<(Q & "<)P M$P 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03 M621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( &Q0;DW)A#K_?0( -\( 8 >&PO=V]R:W-H965T&UL?5;;CILP$/T5Q ($M("I[83M MW]B(H\I[L\3J\[?X^>CRC5!(/X M4=-!+/J>=N7,V*L>?+[L_%"OB#:TE-H$4R-?V/")3@XEOC=Y_X4^:*/@>B5*HV2- M,%^OO O)VLF*6DI+WL:V[DP[C']B--%@ IX(>";@[+^$:")$,P'%QOEQ9<;5 M#T22(N=L\/AX6CW108&>([69I9XT>V?^*6^%FGT481X\M)D)<1@1>(% ,R)0 MMFKR@)]8&N(@4%DA @<2A M9Y: B]C BDHD#KTK27@(E (*V2@0N;RD24Q0A(#Z<9C#M&*&QM09..*6)%R M&"'I$K(2*EM08NM*Q)8$ $E@"13""16Z%E([I4)GMS;;)$Q6$@NMI"YRE>S0 M@C KIX+ _-TC[%JPXPO X)4 0W 2H\BU8(<8A,$K*G"N(S>5<63=1A-F>3;; M*-EDR6HL+PM@76+ H%RWE-U-9A5>R>V?* M^F)VKMY[;,K-7_A8^K\2?JL[X9V95$7+E)8K8Y*JI81/RM]*O3;F04.O4G=CR1T'DO73F_=[M0^AG M/^KJV"WG^[X_/19%][(/==E]:4[A&+_9-6U=]O&R?2VZ4QO*[1A45P4*88JZ M/!SGJ\5X[ZE=+9JWOCHJ.2_G,/^X\?7PNN^'&\5J<2I? MPY^A_W9Z:N-5<1UE>ZC#L3LTQUD;=LOY3_"XD6((&!5_'<*YNSF?#:D\-\WW MX>*W[7(N!D>A"B_],$09#^]A$ZIJ&"GZ^&<:='Z=] MU+PCQ3I2U!$DCBX2?3,1@-%"F<00U0G>B6:=:.HDV;ZUIDZDDL:D2T-U$E%Y MR=LQK!U#[&&%W< M4 V*]^-8/X[ZT8D?1^9!="HML0TC4R@PLV&>=>.IFZ1"UYYF;2$FCBDGJ#!3 MRB!X6 EJAM!*4#99QTR# 7"+YFI0. !"$@3\VEBR"RS M$@;276>$&#EG;6ZQ>:@"I:I*J3II[J9R\3DE3RHGC"4;(9/QQ&,5*%=5RE6@ MP(R.O-6I):JS2GL#&4<\7H'R-:VS-3" 5=ZC(Y:H,+=G/%V!XE6E> 5*3>.' M B%U1(5:&(Q+F?'$XQ4H7^D*47"2"F+8JKRS.L-6X.$*E*XJI3U0;AJCR<\A M(\OM%H]6H&Q5*>F!,M/$K-4-8"8WC% ;X72FGI%'+%+$IAW)FM.DB_.YYMX) M3U6D5%6YKC+35E*JJI2J2&&95MZGDGL?/$F1DE2G)$4*2!_[3J%2,U1GO!>0 M^<5"GJ-(.:I3CB+3H K!L)T1YM:'9RA2ANJ4$$C1J+V(_:<$LD14&D&AK946 M,[YXFB*EJ4YIBA22#TY(A2E5-O]'>>^*YRE2GNJ48$AA^0"Q5[ M#U2D0-4IQ)"2\D$9;ZRQI$=DM1JMB(UKYD\A\GA%BE=-4,;TKB E@J)/'I5* MIY6 7'<)*2D:=-K&3YO9?:*Z)9:29)K:X>2_!37MT^K_P!02P,$ M% @ ;%!N34#]$-5- @ R@< !@ !X;"]W;W)K.&##O7<]\G M7NIKQ>4$*/(>7?%WS'_T!RI&8/9RKEOE 9*\;/& UOT M'9G*D9!7.?ARWKE0$N$&G[AT@41SQR5N&NE)G+IS3&FX[+][_Z22%\D< M$<,E:7[59U[MW-1USOB";@U_(<-G/"44N%H]DI?"VP9B,T]R4NV=6A/9,C%[+Z(T!W?I9Y+L1XF_D/AK16E1_',"1/P9 MPK="^,H^7$)D&L0H292D4Q)/@WBD6#$$5H; 8(BAQC!*HD6$"*I/(WFN6_&$ M5I[0Y-$RWH=&')WDD6+%$%D9(I-!._I]])3AD6+%$%L98I,AT!A&2;J,L('Z M]7@B6I$D5I+$) DUDL3(U4L@M%Z2_Y*NJ%(K56I211I5:H3*@C"%8:9M9&D* MXRR#7NQ'=J+,2I291+%&E!F!DBP*->[RF6K%(FJ)]7V#)DVB/W#0/(LTCA:Z M,1)8/*JRRGU#]%IWS#D2+MYG]8I>".%8^(0;X:T2A74>-/C"93<1?3I6EW' M23]53C"7[^(O4$L#!!0 ( &Q0;DVAH$FW[ , %L1 8 >&PO=V]R M:W-H965T&ULC9A;CZLV$,>_"N)]%]OXQBJ)M+E4K=1*JU.U M?683YZ+#)06R.?WV-83-"3-#LB\!G/_,^&7>'_V995GC;^L=I%];%RZ:8SRK-(,*:C/#T4X6S2M;U5 MLTEY:K)#X=ZJH#[E>5K]-W=9>9Z&//QL^';8[9NV(9I-CNG._>F:OXYOE7^* MKEXVA]P5]:$L@LIMI^$K?UGQI#7H%'\?W+F^N0]:E/>R_-X^_+:9AJSMD4]KMRBS?PZ;9C\-;1AL MW#8]91= ]D;R*]&4+V! A&B"WLWF,NT26>3 MJCP'U24?CFF;=OQ%^>E:MXW=['3_^?&L?>O'3-M)]-'ZZ27SBT3<2I*A9(DE M_*J(?/QK)P35B;E YF(88($5AH$^/'2RNNMDT,V8'*NXLX]O[4K@AAHKG4(WR6Y+.83P,^B^) LH>*)59HJY,$L*_N.1K M)"1,@F$,@$E0!&LX9R@7L8ZKQ/<9^%L2.LL-XPE3VTT4#H5!/G&D%$0F=DF#REY2SF$D5 SQ")\T8V\CNQ3%; MDX[K-*)(=H6 8S MDI!H([2&7/<\#:G([?"5"T1E&:02#U\Q0L*U3UQ(]=#3BO+DN=4(%;U[\AA3 M<4@5HYWIR1JE8XZFBU!ZNMBOZY"/4EK!#&-P^:>DROA=QYH15'JCYWBGMW"G M[S7V-A9[1IBDBB%&4@97J-6CF$,V>O/G"K/%D$WA)5,G*M9X&K%2^Y50*U@1 M+"F?7/H%T:)9_(+/(2E=IG"-ZAP[YH&N!#@N!7#*FR^G/*$<27E*.9+RA/1^ MRM-% <=5 9R8.<=[]9.VRF\TD/1Q=4#Y\D6/-!(6"'>=#='H$H'C&L'"@J?7 M#(8QD9)+;B ;H1R914J9R)@;O)424GH6HYN#8>ZJ77=*KX-U>2J:-M=O6J]? M EY%>[ $[7/^LN!$^[+]B#M[+QA]GNT/GMBP;YP'8 MLY^>O4LWUX?,;9OVUOC[ZG+WQWO.:YYTI\^9;=30'^\E+59=Y M:P_K5Z\YUB;?]D%EX0G& J_,]X?Y>90;1_FK%-D"O/<=BER^_)N8E,472:KX]\A MZ?Q2LPN\?O^1?=,/W@[F*6],7!7_[+?M[F$>SF=;\Y*_%>V/ZI2:84!J/AM& M_[MY-X7%.R6VQG-5-/W_V?-;TU;ED,5**?-?Y]?]H7\]#?D_PO ,02(2P"7 MDP'^$.!? H2:#)!#@/P,$),!:@A0GP'3DH(A(+@$^,%D@!X"]&? ]!C"(2"\ M!,CI"M$0$'V.(>J7R'G^^@7QF+?Y!^BKZ>'D='SB^GA'=(X<>\4,E&>>.EAB"CG./D BB MB''E& RQNY#Y4DBGX@:",@J5UKYVW8;CE,[Z24GY&:)+*J&98"+"3?=1TWUH MNB,F/B-JPDM(!%$H! L9+D6B4B24XEPT*PD*<>$+GSL6QY*$X,Y%&"O27$@(82]4UV%8T748TZ2# MP \<30F9*B6);(H861R@%@? 8LZ<$G% 7DJ0.%OGA[@6C6K1B!;GOK#2L)+2 MD73O4YJ<;4APW_T26<-J[EQC>@*E'-D)F2@EB6R*&+D;HNZ&B+ON-U!(SC0D MK&U!Z.-*(E1)A"AQ[MRK"-2YXUQS]_8=1^1$D\0:UG)G^48U"9DI)8ELBAB9 MRQG>Z#'$7D?H:H!&ZY:%MD=P.HEX *<,1A#.E'36UAHIZ=J,JM):NGU=0N=* M:22;1,96?]%3<\1JX" G+RH$Z1SD5QW66 [>BG+8HP6@QQ=(J?[/E4TWHS2R M1LJ!22>1Y%;1*9TKFT3&+N.])X?-)V=NR\]A8G/88X?*=1GVF'=<"*E!VX60P&826=/(AD82&DEO'E@VF6SL,]YG<]AH MAVYORV$;?<=#>P=D\*9"]^0TLJ:1#8TD-)+22';3X,=.X[L(CFTCW"TY1]I_ M[ON"2[=5BA$46 V1R)>AFVJ-<%\\ET%(%3'?[JK*+#3S'-QT_\SGJ\JP>BW7/\/_+Z=7]H9D]5 MVU9E_P3TI:I:8[.R;S;?SN3;RT%A7MKNK;;OZ_/S\_-!6QV'WP:\RP\4R_\! M4$L#!!0 ( &Q0;DW^T;,:F@0 $$5 8 >&PO=V]R:W-H965T&ULC9C;;N,V$(9?Q?"]5^3P) :.@OP<_@/*7X:<7UIVF_=(81^\;VN3MW]\M#WY[LLZW:' M4)?=I^8<3O'.<]/691]/VY>L.[>AW(^-ZBH#(6Q6E\?3KSVVFW7SVE?' M4WAL%]UK79?MOT6HFLO]4BY_7/AZ?#GTPX5LLSZ7+^&/T/]Y?FSC67:-LC_6 MX=0=F].B#<_WRP=YMU5V:# J_CJ&2W=SO!A2>6J:;\/)K_O[I1@PC94U1 I^OAG#KJ\]CDTO#W^$?W+F'Q,YJGLPK:I_C[N^\/],E\N]N&Y M?*WZK\WEES G9):+.?O?PENHHGQP$OO8-54W_E_L7KN^J> N0%<&\2^/VJ@Y@;J9P,])C\Y&U/]7/;E9MTVET4[S=:Y'!X* M>:?B8.Z&B^/8C?=BMEV\^K:14JRSMR'0K"DF#=QJKHHL1K]V 5P7!9#F\+Z# M+54XP?>@V"34V%Z]2R)A4;,!]!A WP3()1J$2>)&R6F4K&0.P@EA4#:,TC@ MR!UOR;"6#),3\ $L&\"2G*14**E)8VZL@O9.Y2@C*K->0V**'.O&,6XT>'A*2D_EL2>*Q94":Q3Q M1(52>743\+TEGJ"20RCQ1!EJ(PF4QI:H+K4B>(Q*RE&-7YF2 E)J*[7'9J@N M>O8Z88BGJ61P"F154$ZN9'PQ:Z,(,QBI$=J)5&4!/%1!T 4"J1 \"H%!(> 5 M I1QQN.19D2):0<>A," $'!5 91QJ]Q*:_&[G!-J87*=6!G \Q H#R7@X@(H M[5;22R>]P5//2%.CQ$,1:#TI 1<9L^B=H?CYI93 WK><],-QXD$+3$T)"2X" MST5@JDJ!W\K @-$9X^C\4V%JH'DF L-$7#$60%DW5"P"<#FQ990I/SP5@:DN M(<=^&"R*\0_;^=\%)O!,!(Z)^)4!%'1@G->XHF-TJ8\TGH2*EI=284(K6C?& M]W=<*8JAJFXK"D4!:4QRCEI\)8#HUP9 M;2"W*5L\4Q4M7B5^. I%BU*M=.X]?8RH$ISPX"%14RN>TXKA-"YQBEETNU/A M\]PZD6-0,\I(3RV$Q;:RFXVG.K0OXQY=M]@UKZ=^V.*YN7K=!WR 8>,*72_D MW7;:S?L99MI<_+UL7XZG;O'4]'U3CYM7STW3AVA4?(HC=PCE_GI2A>=^.'3Q MN)TV]::3OCG/&Y;9===T\Q]02P,$% @ ;%!N3+.NZ9EMC? ZPA2DJ5)\IXI+C0M\Q@[F3+'P4FA MX62('93BYL\1)(X%W=%KX%FTG0L!5N8];^$[N!_]R7B/+2RU4*"M0$T,- 5] MW!V.6SMS"$\I?HG9=01\HJ:'A@W3/.'Z&N9]WE,S-?X4+2)\>E/@: M%4H;OZ0:K$,ULW@IBK].I]#Q'&?^*VP;D,Z ] ; ID)1^4?N>)D;'(F99M_S M<,6[0^IG4X5@'$7\Y\5;'[V4N_U]SBZ!:,XY3CGI.F?)8)Y]*9%NE3BF_\'3 M;?A^4^$^PO=O%#YL$V2;!%DDR-X0?+AI<2,G2VZ*L-5,%9@V;I,E%0XZ;O(J MNBSL8QKOY%_ZM.W?N&F%MN2,SM]LG'^#Z,!+2>[\"G7^@2V.A,8%\][;9EJS MR7'8SR^(+<^X_ M02P,$% @ ;%!N3>FV7.JV 0 T@, !@ !X;"]W M;W)K\9PS9\;C?#3VV74 GKPJJ5U!.^_[ V.N MZD!Q=V5ZT'C3&*NX1].VS/46>!U!2K)TM[MFB@M-RSSZ3K;,S>"ET'"RQ U* M-V@3N0,A"AC)>9DRXI W!]?F._ MC[5C+6?NX,[(7Z+V74%O**FAX8/T3V9\@+F>3Y3,Q7^%"T@,#THP1V6DBRNI M!N>-FEE0BN*OTRYTW,?IYCJ=8=N = :D"^ FYF%3HJC\"_>\S*T9B9UZW_/P MQ,DAQ=Y4P1E;$>]0O$/OI4RR)&>70#3''*>8=!VS1#!D7U*D6RF.Z3_P=!N^ MWU2XC_#].X7_(<@V";)(D+TCV'\H<2LF^Y"$K7JJP+9QFARIS*#C)*^\R\#> MQD=D?\.G:?_&;2NT(V?C\65C_QMC/*"4W16.4(W 0 T@, !@ !X;"]W;W)K MYYXXC'="\V ; D50I]DZV&LZ&V%XI8?Z> M0.*0T2U]."@^5I)VKX >YG=S;>8C-+V2K0MD5-#%09O=\>3TF(CP&_ M6ACLXDQ")1?$EV!\+3.Z"8) 0N$"@_#;%1Y RD#D9?R9..F<,@"7YS?VIUB[ MK^4B+#R@_-V6KLGH@9(2*M%+]XS#%YCJV5,R%?\-KB!]>%#B^\>.N]UWR;[%-V#413S&F,X&PO=V]R:W-H M965T3L<^N!_#D14GM2MI[/QP9]+>D=) RT?I7\TTV=8ZKFE9"G^*UQ!8GA0@CEJ(UU<23TZ;]3" M@E(4?YEWH>,^S3=YNL#V =D"R%; 7558,Q$[]W[@X8G38X:] MJ8,SMB+>H7B'WFN5YA\*=@U$2\QICLFV,6L$0_8U1;:7XI3]!\_VX8==A8<( M/VRSWR;[!/DN01X)\G\(TCHQP^V&A):'X[O\6SG,9L-;X;E!['U M&U=_ %!+ P04 " !L4&Y-#$^A_;2X_?M1LNNYG5\DD>(Y/*2H;##VV;4 GKPJJ5U.6^^[(V.N;$%Q=V,Z MT'A3&ZNX1],VS'46>!5!2K)DL[EEB@M-BRSZSK;(3.^ET'"VQ/5*3VF(CP&_!0QN M<2:ADHLQS\%XJ'*Z"8) 0ND# \?M"O<@92!"&2\3)YU3!N#R_,[^+=:.M5RX M@WLC_XC*MSD]4%)!S7OIG\SP':9Z]I1,Q?^ *T@,#THP1VFDBRLI>^>-FEA0 MBN*OXRYTW(?Q9G^88.N 9 (D,^ 0\[ Q453^E7M>9-8,Q(Z][WAXXNTQP=Z4 MP1E;$>]0O$/OM=CN=QF[!J(IYC3&),N8.8(A^YPB64MQ2OZ#)^OPW:K"783O M/BA,UPG258(T$J0?"/:?2ER+N?V4A"UZJL V<9H<*4VOXR0OO// WB7Q3?Z% MC]/^R&TCM",7X_%E8_]K8SR@E,T-CE"+'VPV)-0^'+_@V8YC-AK>=-,/8O,W M+OX"4$L#!!0 ( &Q0;DW;::)_MP$ -(# 9 >&PO=V]R:W-H965T MVT-]J#] M38-&<>=-TS+;&^!U!"G)TB2Y8XH+3 GP)&NSJ3 M4,D%\3D87^J")D$02*A<8.!^N\(C2!F(O(S?,R==4@;@^OS*_BG6[FNY< N/ M*'^)VG4%/5!20\,'Z9YP_ QS/;>4S,5_A2M('QZ4^!P52AM74@W6H9I9O!3% M7Z9=Z+B/T\T^FV';@'0&I O@$/.P*5%4_I$[7N8&1V*FWO<\//'NF/K>5,$9 M6Q'OO'CKO==R=WN?LVL@FF-.4TRZCEDBF&=?4J1;*4[I?_!T&[[?5+B/\/T; MA8=M@FR3((L$V1N"#^]*W(BY2]XE8:N>*C!MG"9+*AQTG.25=QG8AS2^R;_P M:=J_<=,*;K\!UL,"8T+QWM_-M.838;#?OY!;/G& MY5]02P,$% @ ;%!N39O6:1ZW 0 T@, !D !X;"]W;W)K&UL=5/;;IPP$/T5RQ\0+RS=IBM RJ:J6JF55JF:/GMA "N^ M4-LLZ=]W; @E*7VQ/>,Y9\Z,Q_EH[)/K #QY5E*[@G;>]T?&7-6!XN[&]*#Q MIC%6<8^F;9GK+? Z@I1DZ6YW8(H+3 1P&C6YU) MJ.1BS%,POM0%W05!(*'R@8'C=H5[D#(0H8Q?,R==4@;@^OS"_BG6CK5,^3C>'#S-L&Y#.@'0!W,8\;$H4E7_DGI>Y-2.Q4^]['IXX.:;8FRHX M8ROB'8IWZ+V6R2')V340S3&G*29=QRP1#-F7%.E6BE/Z#SS=AN\W%>XC?/]* MX7$LDV"+!)DKPCV;TK)&&KGBJP;9PF1RHSZ#C)*^\RL'=I?)._X=.T M?^.V%=J1B_'XLK'_C3$>4,KN!D>HPP^V&!(:'X[O\6RG,9L,;_KY!['E&Y=_ M %!+ P04 " !L4&Y-G<,TF;(Y/*2H;##VV;4 GKPHJ5U.6^^[$V.N;$%Q=V!5!2K)DLSDPQ86F119]%UMDIO=2:+A8XGJEN/U[!FF&G&[I MJ^-)-*T/#E9D'6_@!_B?W<6BQ6:62BC03AA-+-0Y?=B>SFF(CP&_! QN<2:A MDJLQS\'X6N5T$P2!A-('!H[;#1Y!RD"$,OY,G'1.&8#+\RO[YU@[UG+E#AZ- M_"TJW^;T2$D%->^E?S+#%YCJV5,R%?\-;B Q/"C!'*61+JZD[)TW:F)!*8J_ MC+O0<1_&FW0_P=8!R01(9L QYF%CHJC\$_>\R*P9B!U[W_'PQ-M3@KTI@S.V M(MZA>(?>6[$][#-V"T13S'F,298Q-T(Y7C?VOC?& 4C9W.$(M?K#9D%#[<+S'LQW';#2\Z:8?Q.9O7/P# M4$L#!!0 ( &Q0;DT<16[LM@$ -(# 9 >&PO=V]R:W-H965T^C\38U& M"^=-TS#;&Q!5!&G%>)+<,"UD1XLL^DZFR'!P2G9P,L0.6@OS^P@*QYRF]-WQ M+)O6!01F_9DZZI S ]?F=_5.LW==R%A8>4?V4 ME6MS>D=)!;48E'O&\3/,]5Q3,A?_%2Z@?'A0XG.4J&Q<23E8AWIF\5*T>)MV MV<5]G&[X_0S;!O 9P!? 7]%>.+TP'UORN",K8AW M7KSUWDN1WMQG[!*(YICC%,/7,4L$\^Q+"KZ5XLC_@_-M^&Y3X2["=^OLM\DV MP7Z38!$]O\0I!]*W(KYJ)*M>JK!-'&:+"EQZ.(DK[S+P#[P^"9_PZ=I_R9, M(SM+SNC\R\;^UX@.O)3DRH]0ZS_88BBH73C>^K.9QFPR'/;S#V++-R[^ %!+ M P04 " !L4&Y-B(Y/*2H;##VU;4 GKPIJ5U.6^^[ V.N;$%Q=V,ZT'A3&ZNX M1],VS'46>!5!2K)DL[EEB@M-BRSZ3K;(3.^ET'"RQ/5*CFF(CP&_! QN<2:ADK,Q MK\'X6N5T$P2!A-('!H[;!1Y!RD"$,OY,G'1.&8#+\Y7].=:.M9RY@TP2B*:8XQB3+&/F"(;LK,-WJPIW$;[[H#!=)TA7 M"=)(D'X@V'\J<2WF]E,2MNBI MO$:7*D-+V.D[SPS@/[D,0W>0\?I_T[MXW0 MCIR-QY>-_:^-\8!2-C;?.X 0 T@, !D !X;"]W;W)K&UL;5/;;MLP#/T501]0.4[69(%MH.E0=, &!!VV/2LV;0O5Q97DN/O[ M4;+KN9U?))'B.3RDJ&PP]MFU )Z\*JE=3EOONR-CKFQ!<7=C.M!X4QNKN$?3 M-LQU%G@504JR-$ENF>)"TR*+OK,M,M-[*32<+7&]4MS^.8$T0TXW],WQ))K6 M!P,)A;JG-YMCJ==B(\!OP0,;G$FH9*+,<_! M^%KE- F"0$+I P/'[0KW(&4@0ADO$R>=4P;@\OS&_A!KQUHNW,&]D;]%Y=N< M'BBIH.:]]$]F>(2IGD^43,5_@RM(# ]*,$=II(LK*7OGC9I84(KBK^,N=-R' M\6:;3K!U0#H!TAEPB'G8F"@J_\(]+S)K!F+'WG<\//'FF&)ORN",K8AW*-ZA M]UIL]ON,70/1%',:8])ES!S!D'U.D:ZE.*7_P=-U^'95X3;"M^\4'M8)=JL$ MNTBP>T?P^4.)*S&'Y$,2MNBI MO$:7*D-+V.D[SPS@-[%Q^1_0L?I_T[MXW0 MCER,QY>-_:^-\8!2DALQ^1L7?P%02P,$ M% @ ;%!N3?=*-0JV 0 T@, !D !X;"]W;W)K&UL=5/;;IPP$/T5RQ\0+RQ-5BM RJ:J6JF55JG:/GMA "N^4-LLZ=]W M; @A*7VQ/>,Y9\Z,Q_EH[)/K #QY5E*[@G;>]T?&7-6!XN[&]*#QIC%6<8^F M;9GK+? Z@I1DZ6YWRQ07FI9Y])UMF9O!2Z'A;(D;E.+VSPFD&0N:T!?'HV@[ M'QRLS'O>PG?P/_JS18LM++50H)TPFEAH"GJ?'$]9B(\!/P6,;G4FH9*+,4_! M^%(7=!<$@83*!P:.VQ4>0,I A#)^SYQT21F Z_,+^Z=8.]9RX0X>C/PE:M\5 M]$!)#0T?I'\TXV>8Z_E R5S\5[B"Q/"@!'-41KJXDFIPWJB9!:4H_CSM0L=] MG&[N;F?8-B"= >D".,0\;$H4E7_DGI>Y-2.Q4^]['IXX.:;8FRHX8ROB'8IW MZ+V6R2')V340S3&G*29=QRP1#-F7%.E6BE/Z#SS=AN\W%>XC?/]&X7\(LDV" M+!)D;PCV[TK)6&KGBJP;9PF1RHSZ#C)*^\RL/=I?)/7\&G:OW';"NW( MQ7A\V=C_QA@/*&5W@R/4X0=;# F-#\<[/-MIS";#FW[^06SYQN5?4$L#!!0 M ( &Q0;DVA4Z/XM@$ -(# 9 >&PO=V]R:W-H965TT5MJ#]385&<>=-4S/; M&N!E!"G)DM7JFBDN-,W3Z#N9/,7.2:'A9(CME.+F[0@2^XRNZ8?C2=2-"PZ6 MIRVOX1G<[_9DO,4FEE(HT%:@)@:JC-ZN#\=MB(\!?P3T=G8FH9(SXDLP?I89 M705!(*%P@8'[[0)W(&4@\C+^C9QT2AF \_,'^T.LW==RYA;N4/X5I6LRNJ>D MA(IWTCUA_P/&>G:4C,7_@@M('QZ4^!P%2AM74G36H1I9O!3%7X==Z+CWP\UF M-\*6 V*&WK<\//'ZD/C>%,$96Q'OO'CKO9=\ MO=^E[!*(QICC$)/,8Z8(YMFG%,E2BF/R'SQ9AF\6%6XB?/-%X?4RP7:18!L) MME$;KZ5N!2S_Y:$S7JJP-1QFBPIL--QDF?>:6!OD_@FG^'#M#]R4PMMR1F= M?]G8_PK1@9>RNO(CU/@/-AD2*A>.-_YLAC$;#(?M^(/8](WS=U!+ P04 M" !L4&Y-]2Y&R+8! #2 P &0 'AL+W=O?2=39GCX*30<#;$#DIQ\^<$$L>"IO35\23:S@4'*_.> MM_ =W(_^;+S%%I9:*-!6H"8&FH+>I\?3/L3'@)\"1KLZDU#)!?$Y&%_J@B9! M$$BH7&#@?KO" T@9B+R,WS,G75(&X/K\ROXIUNYKN7 +#RA_B=IU!3U04D/# M!^F>E/@<%4H;5U(-UJ&:6;P4Q5^F7>BXC]/-;3K# MM@'9#,@6P"'F85.BJ/R1.U[F!D=BIM[W/#QQ>LQ\;ZK@C*V(=UZ\]=YKF1[N MP?/MN&[386["-^ML]\EVP3[38)])-C_ M1Y"^*7$KYJU*MNJI M/&:;*DPD''25YYEX&]S^*;_ N?IOT;-ZW0EES0^9>- M_6\0'7@IR8T?H&UL M;5-M;YLP$/XKEG] G1#:;1$@-9VF3FJEJ-.VSPX<8-4OU#:A^_<[&$HQA=\ M=]SSW'/GE=0NIZWWW9XQ5[:@N+LQ'6C\4QNKN$?7-LQU%G@5 M04JR9+.Y8XH+38LLQHZVR$SOI=!PM,3U2G'[YP#2##G=TDO@132M#P%69!UO MX ?XG]W1HL=FEDHHT$X832S4.;W?[@]IR(\)OP0,;F&3T,G)F-?@?*]RN@F" M0$+I P/'XPP/(&4@0AEO$R>=2P;@TKZP?XN]8R\G[N#!R-^B\FU./U-2043,T_P1DDI@9-8,Q(ZS[WBXXNT^P=F4(1A'$?^A>(?1<[']LLO8.1!- M.8<2R5J)0_(?/%F'[U85[B)\]T%ANDZ0KA*DD2#]0'![U>): MSMU5$;:8J0+;Q&URI#2]CIN\B,X+>Y_$._F7/F[[,[>-T(Z;C?.OC?& M4C8WN$(M/K#9D5#[8'Y"VXYK-CK>=-,+8O,S+OX"4$L#!!0 ( &Q0;DT> MJ(SWN $ -(# 9 >&PO=V]R:W-H965TF]TJV<++$]5H+^_<(R@P9W=(WQY.L&Q\<+$\[4<-/\+^Z MDT6+S2REU- Z:5IBHE A'*^#-QTCEE "[/;^R/L7:LY2PB>DA(JT2O_9(:O M,-5S3X@,+PH 1S%$:YN)*B=][HB06E:/$Z[K*-^S#>7"<3;!W )P"? M ?N8AXV)HO('X46>6C,0._:^$^&)MP>.O2F",[8BWJ%XA]Y+OKV]2=DE$$TQ MQS&&+V/F"(;L\?CF_P/'Z?]A["U;!TY&X\O&_M?&>,! MI6RN<(0:_&"SH:#RX7B#9SN.V6AXTTT_B,W?./\'4$L#!!0 ( &Q0;DT0 M]TUXM0$ -(# 9 >&PO=V]R:W-H965TF+[1G/.7-F M/"XF;9YL#^#0BQ3*EKAW;C@08NL>)+-7>@#E;UIM)'/>-!VQ@P'61) 4A";) M-9&,*UP5T7BIQBE\=C[SK77"0JAA8!S_ _1Q. MQEMD96FX!&6Y5LA 6^+;]'#,0WP,^,5ALILS"I6X R$"D9?QO'#B-64 ;L^O[%]C[;Z6,[-PI\5OWKB^Q#<8-="R4;A'/=W# M4L\GC);BO\$%A \/2GR.6@L;5U2/UFFYL'@IDKW,.U=QG^:;+%U@^P"Z .@* MN(EYR)PH*O_"'*L*HR=DYMX/+#QQ>J"^-W5PQE;$.R_>>N^EHDE:D$L@6F*. M["K,(S]XI_ ]!ODN01X+\'4'VH<2]F/Q# M$K+IJ033Q6FRJ-:CBI.\\:X#>TOCF[R%S]/^G9F.*XO.VOF7C?UOM7;@I217 M?H1Z_\%60T#KPO&S/YMYS&;#Z6'Y063]QM5?4$L#!!0 ( &Q0;DU@9,RO MM@$ -(# 9 >&PO=V]R:W-H965T-ANM "F;*DJD5EJE:OOLA0&L^$)LLR1_7]NPE*;T!<\,YYRY>)P- MVKS:%L"A=RF4S7'K7'<@Q)8M2&9O= ?*_ZFUD *3@;97DIF/HX@])#C#;X&7GC3NA @1=:Q!KZ#^]&=C/?( MK%)Q"'BHQ..BTG%5^*9._CR54\ATG_2ELGT(E 9\)N'WL9 M$\7*OS#'BLSH 9EQ]AT+5[PY4#^;,@3C*.(_7[SUT4M!DUU&+D%HPAQ'#%U@ M-C.">/4Y!5U+<:3_T.DZ?;M:X3;2M\OLZ7\$TE6!- JD?[5X^ZG%-MO8E]_J'RX@./N[0?8\=R4/X%[?T),V8)@YD;U(-V76FG!K MU0TRO@56!)#BA27)+!.LD M+K*0.^HB4X/EG82C1F80@NF_!^!JS'&*+XGGKFFM3Y BZUD#O\#^[H_:1611 MJ3H!TG1*(@UUCN_3_6'G\0'PIX/1K/;(=W)2ZM4'WZL<)]X0<"BM5V!N.<,# M<.Z%G(VW61,O)3UQO;^H/X7>72\G9N!!\9>NLFV.[S"JH&8#M\]J_ 9S/SN, MYN9_P!FX@WLGKD:IN F_J!R,56)6<58$>Y_63H9UG/4OM#B!S@1Z12!3H>#\ MD5E69%J-2$]GWS-_Q>F>NK,I?3(<1?CFS!N7/1+V>GK+4V!5/X\I6?XKBG]02P,$% @ M;%!N3;^YJ;3< 0 04 !D !X;"]W;W)K&UL M=53;CML@$/T5Q 2L] M27!"HVA/!&L[G*<^=U9Y*J^&MQV<%=)7(9CZ?0(NAPS'^)YX;NO&N 3)TY[5 M\!W,C_ZL;$1FE;(5T.E6=DA!E>''^'A*'-X#7EH8]&*/7"<7*5]=\*7,<.0* M @Z%<0K,+C=X LZ=D"WCUZ2)9TM'7.[OZI]\[[:7"]/P)/G/MC1-A@\8E5"Q M*S?/QM7-O.K\.D?Z>% M"70BT!6!C$:^\H_,L#Q5N;\X/E)[-H5+^J/PWVSQVF9O.8TW*;DY MH0ES&C%T@8EG!+'JLP4-69SH.SH-TS?!"C>>OEFZ'_XCL T*;+W ]I\6MZL6 M0YA=V&07--D%!/8KDQ F"9OL@R;[@,!A91+"? B;)$&3Y+T C58F(FZK;3Z"*-'01_72LI#=A2H@=[ MJHU]C^: 0V7<-K%[-4[E&!C93P\.F5^]_ ]02P,$% @ ;%!N37!VI%$D M P U0P !D !X;"]W;W)K&ULE5=M;YLP$/XK MB.\K]F'S$B61VJ33)FU2U6G;9YHX"2I@!D[2_?L90VDP1Y?F0\#FN;OGSGX. M,S_+ZKD^"*&5Z].8@\J6]D*0K]9">K/%%Z6.V]NJQ$LC5& M>>8!(8&7)VGA+N=F[J%:SN5196DA'BJG/N9Y4OV]$YD\+USJODX\ION#:B:\ MY;Q,]N*'4#_+ATJ/O-[+-LU%4:>R<"JQ6[BW='8/O#$PB%^I.-<7]TZ3RI.4 MS\W@ZW;ADH:1R,1&-2X2?3F)E:;K6>O9TQ( YMZI<=1A[EH, M###^$+/",&R(68\QM$=XFF5/%3"J=X"$X!8-#!-8-!#,$'&/("*H@_C_ MJ:[C4:J4,Q](/*$=2G"=$R26;PN=C(+%A$63DHE-"%R MHPD=]#=&/\C$3C6WH;ZOVH-V.U"R[#XBO/Y+9OD/4$L#!!0 ( &Q0;DV: MP,!,[0$ .P$ 9 >&PO=V]R:W-H965TPS*WO+,J<3XKV YQ%("?&B/A] LKG(MR%[XZ7ONV4<: R'TD+WT!] M'\]"6VAEJ7L&@^SY$ AHBO!I=SQE!F\!/WJ8Y68?F$HNG+\:XW-=A)$1!!0J M91B(7J[P#)0:(BWCU\(9KBE-X';_SO[1UJYKN1 )SYS^[&O5%>$^#&IHR$35 M"Y\_P5)/$@9+\5_@"E3#C1*=H^)4VF]035)QMK!H*8R\N;4?[#J[D^2PA/D# M\!* UP#L:G&)K/(/1)$R%WP.A.O]2,POWAVQ[DUEG+85]DR+E]I[+7$R:#BTV#O^,:[7N4G;*?U+]R] U^):/M!!A>N M],S;R6PX5Z#51 ^Z9YU^>E:#0J/,-M-[X2Z@,Q0?E[<%K0]<^0=02P,$% M @ ;%!N3303V5&) @ W0@ !D !X;"]W;W)K&ULC5;9CILP%/T5Q <,F)V(($TVM5(K15--^^P0)Z !3&TGF?Y];>,A+,Z2 MAV!?SCGW7&.N22Z8?- <(69\5F5-YV;.6#.S+)KEJ(+T!3>HYG<.F%20\2DY M6K0A".XEJ2HMQ[8#JX)%;::)C&U)FN 3*XL:;8E!3U4%R;\%*O%E;@+S*_!6 M'',F E::-/"(?B'VWFP)GUF=RKZH4$T+7!L$'>;F*YAM@"1(Q.\"76AO;(A2 M=AA_B,GW_=RTA2-4HHP)"<@O9[1$92F4N(^_2M3L<@IB?_REOI'%\V)VD*(E M+O\4>Y;/S<@T]N@ 3R5[PY=O2!7DFX:J_@(\,EE?]&=J(,5TJ% M6ZG@9WLM:GF]M'?"4-'T!$<1G([ <]\CN(K@/DOP%,&[$KR[!%\1_&V% M>H%0*Q ^WBCK%N/W//J^VZ]YD"?2YHDT1F.]0*P5B)\P&D^, M>[:138^GYE M:S+=6%-PH^4!C40T;E9@ND>/][T>XL?G5$ MIQ[%EV"V IKX6IS=LK-?Y=N#_R+U[425NJ+@>',.6?&0#YQ\2); M !6\,MK+8]@J-1P0DF4+C,@'/D"O=VHN&%%Z*1HD!P&DLDF,(AQ%*6*DZ\,B MM[&S*'(^*MKU37,T#4\F%\Q>S^%(=P\@8 @JE,@Q$#U=X M DH-D;;Q>^8,%TF3N)Z_L7^RM>M:+D3"$Z>_NDJUQW 7!A749*3JF4^?8:XG M"8.Y^*]P!:KAQHG6*#F5]AN4HU2O!4[V.;H:HAES M@[EK/%J=1@:BL?=0!B4?>_L&K*++57_$]C3_@[MWXAL13=?+X,*5OA/VY-:< M*]!6H@?=WE8_3/%R#F 0 +@4 !D !X;"]W;W)K&UL?91A MKYL@%(;_BO$'7!2U=HV:K'=9MF1+FKOL[C/58S47Q &M=_]^@-8X9?U2X/"> M]SF'(MG Q9ML )3WSF@G<[]1JC\@),L&&)%/O(=.[]1<,*+T4ER0[ 60RB8Q MBG 0[! C;><7F8V=1)'QJZ)M!R?AR2MC1/PY N5#[H?^/?#27AIE JC(>G*! M'Z!^]B>A5VAVJ5H&G6QYYPFH<_]C>#BF1F\%KRT,]>]G(F$9TY_M95JQ74 MY$K5"Q^^P-1/XGM3\]_@!E3+326:47(J[:]77J7B;'+1I3#R/HYM9\=AW(GN M:>X$/"7@.0&/O8P@6_DGHDB1"3YX8CS[GIB_.#Q@?3:E"=JCL'NZ>*FCMP+O MH@S=C-&D.8X:O-3$R:Q!VG^&8"<$6X/X'TB\@HR:U&HZJXGB%(?8S8FDU$E*'?&PO=V]R:W-H965TBAK)7@ Y M61*C"$=1AAAIN[#(;>P@BIR?%6T[.(A GADCXO<6*!\V81R^!Y[;NE$F@(J\ M)S5\!_6C/PB]0Y/*J670R99W@8!J$S[%ZWUF\!;PTL(@K]:!J>3(^:O9?#EM MPL@8 @JE,@I$/RZP TJ-D+;Q:]0,IY2&>+U^5_]D:]>U'(F$':<_VY-J-N$J M#$Y0D3-5SWSX#&,]BS 8B_\*%Z :;ISH'"6GTOX'Y5DJSD85;861-_=L._L< MW$F:C30_ 8\$/!%T[G\1DI&0_"\A'0GI!R&UW7*EV-[LB2)%+O@0"/=V>V(^ MHGB=ZNZ7)FB;;<]T>Z2.7@J<93FZ&*$1LW48?(W!R2UF=X^))P32#B8;V&=C MB^]3+/ LA0=SB]C?(Y:1WT7B;49B^>F-BW3FPH=9^).DWB2I1V#><8=96DSG MNKF*[&_FQ@-\C)?QXUQQ?P_\2V<67M,+C^FE7R#S"F0>@=6LF.R^&'Q;M$N$ MKCYN!J*V@T,&)3]WRKS^J^@TFYZPN1RS^$[/+#=B/F3
MO2 5YPJTS>A!-Z/1,W;:4*B462[U6KA)XS:*]^,01=,D+_X 4$L#!!0 ( M &Q0;DT&PO=V]R:W-H965TXKINP M:?E@X'AW[ST"5PY2/>L&P$0O@G=Z'3?&]/>$Z+H!P?2=[*'#G:-4@AE*J=+&=JDIY-KSM8***TB?/Y:_5/SCMZV3,-6\E_M@?3 MK.-5'!W@R,[JS]I(,59!*8*]^+'M MW#CXG3P=T\()=$R@4P)R_RLA&Q.RMX2%,^^5.:L?F6%5J>00*?]G]B?0^ MP\.L;="=G=M#MQJCEXH6RY)<;*$1L_$8.L.D$X)@]8F"AB@V]":=OB?8!A"K M,$,6-)&Y_,4[$ZLK$QZS=)C.FTB+/%D45UIN<4E8RB(H91&0\N%*BL?D�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end XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 96 207 1 false 42 0 false 5 false false R1.htm 1001 - Document - Document And Entity Information Sheet http://www.entremed.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.entremed.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] Sheet http://www.entremed.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets [Parenthetical] Statements 3 false false R4.htm 1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.entremed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1005 - Statement - Condensed Consolidated Statement of Stockholders' Equity Sheet http://www.entremed.com/role/CondensedConsolidatedStatementOfStockholdersEquity Condensed Consolidated Statement of Stockholders' Equity Statements 5 false false R6.htm 1006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.entremed.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 1007 - Disclosure - Basis of Presentation Sheet http://www.entremed.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 1008 - Disclosure - Acquisition of Abbreviated New Drug Applications Sheet http://www.entremed.com/role/AcquisitionOfAbbreviatedNewDrugApplications Acquisition of Abbreviated New Drug Applications Notes 8 false false R9.htm 1009 - Disclosure - Intangible Assets Sheet http://www.entremed.com/role/IntangibleAssets Intangible Assets Notes 9 false false R10.htm 1010 - Disclosure - Foreign Currency Translation Sheet http://www.entremed.com/role/ForeignCurrencyTranslation Foreign Currency Translation Notes 10 false false R11.htm 1011 - Disclosure - Investments Sheet http://www.entremed.com/role/Investments Investments Notes 11 false false R12.htm 1012 - Disclosure - Inventories Sheet http://www.entremed.com/role/Inventories Inventories Notes 12 false false R13.htm 1013 - Disclosure - Research and Development Sheet http://www.entremed.com/role/ResearchAndDevelopment Research and Development Notes 13 false false R14.htm 1014 - Disclosure - License Arrangements Sheet http://www.entremed.com/role/LicenseArrangements License Arrangements Notes 14 false false R15.htm 1015 - Disclosure - Note Payable Sheet http://www.entremed.com/role/NotePayable Note Payable Notes 15 false false R16.htm 1016 - Disclosure - Stockholders' Equity Sheet http://www.entremed.com/role/StockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 1017 - Disclosure - Net Loss Per Share Sheet http://www.entremed.com/role/NetLossPerShare Net Loss Per Share Notes 17 false false R18.htm 1018 - Disclosure - Stock-Based Compensation and Warrants Sheet http://www.entremed.com/role/StockBasedCompensationAndWarrants Stock-Based Compensation and Warrants Notes 18 false false R19.htm 1019 - Disclosure - Income Taxes Sheet http://www.entremed.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 1020 - Disclosure - Related Party Transactions Sheet http://www.entremed.com/role/RelatedPartyTransactions Related Party Transactions Notes 20 false false R21.htm 1021 - Disclosure - New Accounting Pronouncements Sheet http://www.entremed.com/role/NewAccountingPronouncements New Accounting Pronouncements Notes 21 false false R22.htm 1022 - Disclosure - Commitments Sheet http://www.entremed.com/role/Commitments Commitments Notes 22 false false R23.htm 1023 - Disclosure - Subsequent Event Sheet http://www.entremed.com/role/SubsequentEvent Subsequent Event Notes 23 false false R24.htm 1024 - Disclosure - Acquisition of Abbreviated New Drug Applications (Tables) Sheet http://www.entremed.com/role/AcquisitionOfAbbreviatedNewDrugApplicationsTables Acquisition of Abbreviated New Drug Applications (Tables) Tables http://www.entremed.com/role/AcquisitionOfAbbreviatedNewDrugApplications 24 false false R25.htm 1025 - Disclosure - Intangible Assets (Tables) Sheet http://www.entremed.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.entremed.com/role/IntangibleAssets 25 false false R26.htm 1026 - Disclosure - Stock-Based Compensation and Warrants (Tables) Sheet http://www.entremed.com/role/StockBasedCompensationAndWarrantsTables Stock-Based Compensation and Warrants (Tables) Tables http://www.entremed.com/role/StockBasedCompensationAndWarrants 26 false false R27.htm 1027 - Disclosure - Basis of Presentation (Details Textual) Sheet http://www.entremed.com/role/BasisOfPresentationDetailsTextual Basis of Presentation (Details Textual) Details http://www.entremed.com/role/BasisOfPresentation 27 false false R28.htm 1028 - Disclosure - Acquisition of Abbreviated New Drug Applications (Details) Sheet http://www.entremed.com/role/AcquisitionOfAbbreviatedNewDrugApplicationsDetails Acquisition of Abbreviated New Drug Applications (Details) Details http://www.entremed.com/role/AcquisitionOfAbbreviatedNewDrugApplicationsTables 28 false false R29.htm 1029 - Disclosure - Acquisition of Abbreviated New Drug Applications (Details Textual) Sheet http://www.entremed.com/role/AcquisitionOfAbbreviatedNewDrugApplicationsDetailsTextual Acquisition of Abbreviated New Drug Applications (Details Textual) Details http://www.entremed.com/role/AcquisitionOfAbbreviatedNewDrugApplicationsTables 29 false false R30.htm 1030 - Disclosure - Intangible Assets (Details) Sheet http://www.entremed.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://www.entremed.com/role/IntangibleAssetsTables 30 false false R31.htm 1031 - Disclosure - Intangible Assets (Details 1) Sheet http://www.entremed.com/role/IntangibleAssetsDetails1 Intangible Assets (Details 1) Details http://www.entremed.com/role/IntangibleAssetsTables 31 false false R32.htm 1032 - Disclosure - Intangible Assets (Details Textual) Sheet http://www.entremed.com/role/IntangibleAssetsDetailsTextual Intangible Assets (Details Textual) Details http://www.entremed.com/role/IntangibleAssetsTables 32 false false R33.htm 1033 - Disclosure - Investments (Details Textual) Sheet http://www.entremed.com/role/InvestmentsDetailsTextual Investments (Details Textual) Details http://www.entremed.com/role/Investments 33 false false R34.htm 1034 - Disclosure - Inventories (Details Textual) Sheet http://www.entremed.com/role/InventoriesDetailsTextual Inventories (Details Textual) Details http://www.entremed.com/role/Inventories 34 false false R35.htm 1035 - Disclosure - Note Payable (Details Textual) Sheet http://www.entremed.com/role/NotePayableDetailsTextual Note Payable (Details Textual) Details http://www.entremed.com/role/NotePayable 35 false false R36.htm 1036 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.entremed.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://www.entremed.com/role/StockholdersEquity 36 false false R37.htm 1037 - Disclosure - Net Loss Per Share (Details Textual) Sheet http://www.entremed.com/role/NetLossPerShareDetailsTextual Net Loss Per Share (Details Textual) Details http://www.entremed.com/role/NetLossPerShare 37 false false R38.htm 1038 - Disclosure - Stock-Based Compensation and Warrants (Details) Sheet http://www.entremed.com/role/StockBasedCompensationAndWarrantsDetails Stock-Based Compensation and Warrants (Details) Details http://www.entremed.com/role/StockBasedCompensationAndWarrantsTables 38 false false R39.htm 1039 - Disclosure - Stock-Based Compensation and Warrants (Details 1) Sheet http://www.entremed.com/role/StockBasedCompensationAndWarrantsDetails1 Stock-Based Compensation and Warrants (Details 1) Details http://www.entremed.com/role/StockBasedCompensationAndWarrantsTables 39 false false R40.htm 1040 - Disclosure - Stock-Based Compensation and Warrants (Details 2) Sheet http://www.entremed.com/role/StockBasedCompensationAndWarrantsDetails2 Stock-Based Compensation and Warrants (Details 2) Details http://www.entremed.com/role/StockBasedCompensationAndWarrantsTables 40 false false R41.htm 1041 - Disclosure - Stock-Based Compensation and Warrants (Details 3) Sheet http://www.entremed.com/role/StockBasedCompensationAndWarrantsDetails3 Stock-Based Compensation and Warrants (Details 3) Details http://www.entremed.com/role/StockBasedCompensationAndWarrantsTables 41 false false R42.htm 1042 - Disclosure - Stock-Based Compensation and Warrants (Details Textual) Sheet http://www.entremed.com/role/StockBasedCompensationAndWarrantsDetailsTextual Stock-Based Compensation and Warrants (Details Textual) Details http://www.entremed.com/role/StockBasedCompensationAndWarrantsTables 42 false false R43.htm 1043 - Disclosure - Income Taxes (Details Textual) Sheet http://www.entremed.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) Details http://www.entremed.com/role/IncomeTaxes 43 false false R44.htm 1044 - Disclosure - Related Party Transactions (Details Textual) Sheet http://www.entremed.com/role/RelatedPartyTransactionsDetailsTextual Related Party Transactions (Details Textual) Details http://www.entremed.com/role/RelatedPartyTransactions 44 false false R45.htm 1045 - Disclosure - Commitments (Details Textual) Sheet http://www.entremed.com/role/CommitmentsDetailsTextual Commitments (Details Textual) Details http://www.entremed.com/role/Commitments 45 false false R46.htm 1046 - Disclosure - Subsequent Event (Details Textual) Sheet http://www.entremed.com/role/SubsequentEventDetailsTextual Subsequent Event (Details Textual) Details http://www.entremed.com/role/SubsequentEvent 46 false false All Reports Book All Reports casi-20180930.xml casi-20180930.xsd casi-20180930_cal.xml casi-20180930_def.xml casi-20180930_lab.xml casi-20180930_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 64 0001144204-18-059603-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-18-059603-xbrl.zip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